Document:

EX-10.24

 Exhibit 10.24 
 *** INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 
  
 EXCLUSIVE LICENSE AGREEMENT 
  
 between 
  
 THE
REGENTS OF THE UNIVERSITY OF CALIFORNIA 
  
 and 

 
 FIVE PRIME THERAPEUTICS, INC. 

 
 for 

 
 RECEPTORS FOR FIBROBLAST GROWTH FACTORS 

 
 UC Case No. *** 

 TABLE OF CONTENTS 

 

					
	Article No.         Title	 	Page
		
	 BACKGROUND
	 	1
			
	 1.
	 	DEFINITIONS	 	4
			
	 2.
	 	GRANTS	 	13
			
	 3.
	 	AFFILIATION AGREEMENTS	 	15
			
	 4.
	 	RIGHT TO GRANT SUBLICENSES	 	17
			
	 5.
	 	PAYMENT TERMS	 	19
			
	 6.
	 	LICENSE ISSUE FEE	 	21
			
	 7.
	 	PAYMENTS ON SUBLICENSES AND FURTHER SUBLICENSES	 	21
			
	 8.
	 	ROYALTIES	 	22
			
	 9.
	 	MILESTONE PAYMENTS	 	22
			
	 10.
	 	DUE DILIGENCE	 	23
			
	 11.
	 	PROGRESS AND ROYALTY REPORTS	 	24
			
	 12.
	 	BOOKS AND RECORDS	 	26
			
	 13.
	 	LIFE OF THE AGREEMENT	 	27
			
	 14.
	 	TERMINATION BY THE REGENTS	 	28
			
	 15.
	 	TERMINATION BY LICENSEE	 	29
			
	 16.
	 	DISPOSITION OF LICENSED PRODUCTS UPON TERMINATION OR EXPIRATION	 	29
			
	 17.
	 	USE OF NAMES AND TRADEMARKS	 	29

  
 ***
INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED. 
  

					
		 		 	

					
	 18.
	 	LIMITED WARRANTY	 	30
			
	 19.
	 	LIMITATIONS OF LIABILITY	 	31
			
	 20.
	 	PATENT PROSECUTION AND MAINTENANCE	 	32
			
	 21.
	 	PATENT MARKING	 	35
			
	 22.
	 	PATENT INFRINGEMENT	 	35
			
	 23.
	 	INDEMNIFICATION	 	38
			
	 24.
	 	NOTICES	 	41
			
	 25.
	 	ASSIGNABILITY	 	42
			
	 26.
	 	WAIVER	 	43
			
	 27.
	 	FORCE MAJEURE	 	43
			
	 28.
	 	GOVERNING LAWS; VENUE; ATTORNEYS’ FEES	 	43
			
	 29.
	 	GOVERNMENT APPROVAL OR REGISTRATION	 	44
			
	 30.
	 	COMPLIANCE WITH LAWS	 	44
			
	 31.
	 	CONFIDENTIALITY	 	45
			
	 32.
	 	MISCELLANEOUS	 	47

  
 ***
INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED. 
  

					
		 	ii	 	***_FivePrime

 CONFIDENTIAL 
 UC Case No. *** 
 EXCLUSIVE LICENSE AGREEMENT 

for 
 RECEPTORS FOR
FIBROBLAST GROWTH FACTORS 
 This exclusive license agreement (“Agreement”) is made effective this Seventh day
of September 2006 (“Effective Date”), by and between The Regents of the University of California, a California corporation, having its statewide administrative offices at 1111 Franklin Street, 12th Floor, Oakland, California
94607-5200 and acting through its Office of Technology Management, University of California San Francisco, 185 Berry Street, Suite 4603, San Francisco, California 94107 (“The Regents”) and Five Prime Therapeutics Inc., a Delaware
corporation, having a principal place of business at 1650 Owens Street, Suite 200, San Francisco, CA 94158 (“FivePrime”). 
 BACKGROUND 
 A.        Certain inventions,
generally characterized as Fibroblast Growth Factor Receptors (FGFRs; collectively the “Invention”), were made in the course of research at the University of California, San Francisco, by Drs. Lewis T. Williams, Daniel E. Johnson,
and Pauline E. Lee and are claimed in the Patent Rights as defined below. 

B.        Drs. Williams, Johnson, and Lee were employees of the Howard Hughes Medical Institute
(“HHMI”) and members of the faculty of The University of California, San Francisco, at the time the Invention was conceived and developed. 
 C.        The development of the Invention was sponsored in part by the Department of Health and Human Services and, as a consequence, this license is subject to
overriding obligations to the United States Federal Government under 35 U.S.C. §§ 200-212 and applicable regulations including a non-exclusive, non-transferable, irrevocable, paid-up license to practice or have practiced the Invention for
or on behalf of the United States Government throughout the world. 

  
 ***
INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED. 
  

					
		 	1	 	***_FivePrime

 D.        HHMI assigned its rights in the Invention
to The Regents under the terms of the interinstitutional agreement with HHMI having UC Control No. *** (“HHMI Interinstitutional Agreement”), and accordingly, The Regents has the authority to license the entire interest in
the Invention and any patent rights claiming it. Under the terms of the HHMI Interinstitutional Agreement, HHMI has reserved nonexclusive, paid-up, royalty-free, irrevocable licenses, with no right to sublicense others, to make and use the invention
for research purposes. 
 E.        FivePrime and The Regents executed a Letter of
Intent (UC Control No. ***) with an effective date of March 7, 2006, under which the parties agreed, among other things, to negotiate an agreement under which The Regents would license to FivePrime certain of The Regents’ rights for
the commercial development of the Invention. 
 F.        FivePrime now wishes to
license such rights from The Regents, in accordance with the terms and conditions set forth herein and The Regents is willing to grant those rights so that the Invention may be developed and the benefits enjoyed by the general public. 

G.        The scope of such rights granted by The Regents is intended to extend to the scope of
the patents and patent applications in Patent Rights, but only to the extent that The Regents has proprietary rights in and to such Patent Rights. 
 H.        FivePrime is a “small business firm” as defined in 15 U.S.C. §632. 

I.          Both parties recognize and agree that royalties are due under this
Agreement with respect to products and methods and that such royalties will be paid with respect to both pending patent applications and issued patents, in accordance with the terms and conditions set forth herein. 

J.          Both parties recognize and agree that royalties due under this Agreement
will be based on Licensee’s, Sublicensee’s, or a Further Sublicensee’s (as defined below) last act of infringement of Patent Rights within the control of Licensee, Sublicensee or a Further 

  
 ***
INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED. 
  

					
		 	2	 	***_FivePrime

 
Sublicensee, regardless of whether Licensee, Sublicensee or a Further Sublicensee had control over prior infringing acts; the parties intend that royalties due under this Agreement will be
calculated based on the Net Sales of the product resulting from the last act of infringement by Licensee and its Sublicensees or Further Sublicensees. 

  
 ***
INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED. 
  

					
		 	3	 	***_FivePrime

 The parties agree as follows: 

 

	1.	DEFINITIONS 

 As used in this Agreement, the
following capitalized terms, whether used in the singular or plural, shall have the following meanings: 
  

	 	1.1.	“Affiliate,” with respect to FivePrime or any Sublicensee, means any entity which, directly or indirectly, Controls FivePrime or such Sublicensee, is
Controlled by FivePrime or is under common Control with FivePrime. “Control” means (a) having the actual, present capacity to elect a majority of the directors of such affiliate; (ii) having the power to direct at least
fifty percent (50%) of the voting rights entitled to elect directors; or (b) in any country where the local law will not permit foreign equity participation of a majority, ownership or control, directly or indirectly, of the maximum
percentage of such outstanding stock or voting rights permitted by local law. 

  

	 	1.2.	“Affiliation Agreement” means an agreement entered into by FivePrime with any of its Affiliates governing such Affiliates’ license under the
Patent Rights, as further described in Article3. 

  

	 	1.3.	“Attributed Income” means the total gross proceeds received by Licensee in consideration of the grant of a Sublicense or Further Sublicense, excluding
the consideration described in Paragraph 1.3.1, and less the expenses described in Paragraph 1.3.2. 

 1.3.1
Exclusions: 
 (a)        *** 

(b)        *** 
 (c)        *** 

1.3.2. Past research and development expenses specifically related to Sublicensed Product(s), including: 

(a)        *** 

  
 ***
INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED. 
  

					
		 	4	 	***_FivePrime

 (b)        *** 

(c)        *** 
 (d)        *** 

(e)        *** 

 

	 	1.4.	“Combination Product” means a product that is combined with (i.e., contains, includes or incorporates) at least one Licensed Product and at least one
product not covered by the Licensed Patents (a “Combination Product Component”), where (a) if such Combination Product Component were removed from such combined product, the manufacture, use, Sale or import of the remainder of
the combined product in or into a particular country would infringe, but for a license, the Patent Rights in such country, (b) such Combination Product Component ***, and (c) the market price of such combined product is or would be
higher than the market price for such Licensed Product due to its inclusion of the Combination Product Component. By way of illustration and not limitation, an example of a Combination Product would be an antibody to a fibroblast growth factor
receptor, which is covered by the Patent Rights, sold with an antibody to a vascular endothelial cell growth factor, which is not covered by the Patent Rights. 

 

	 	1.5.	“Commercially Reasonable Efforts” means those efforts and resources that would be used by Licensee with regard to the diligent development, manufacture
and commercialization of pharmaceutical products of similar market and profit potential, at a similar stage in development or product life (including without limitation the promptness with which such efforts and resources would be applied) as the
applicable Licensed Product. 

  

	 	1.6.	“FDA” means the United States Food and Drug Administration and its foreign equivalents. 

  
 ***
INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED. 
  

					
		 	5	 	***_FivePrime

	 	1.7.	“Field of Use” means all human therapeutic, diagnostic and prognostic uses, excluding the provision of Licensed Services. For purposes of this
Paragraph 1.7, “Licensed Services” means any “fee for services” provided by Licensee to independent third parties (e.g., parties other than its Affiliates, Joint Ventures, Sublicensees, or collaborators who are working
with or assisting FivePrime with the development, manufacture, Sale, marketing or importation of Licensed Products) (a) which services involve the use but not the Sale) of a Licensed Product, or the use of a Licensed Method (other than with
respect to the manufacture, use, Sale or importation, of a Licensed Product), and (b) for which services (or results of such services) consideration is paid. By way of example, use of a Licensed Product to screen a small-molecule library
provided by an independent third party, in exchange for payment by such third party, would constitute the provision of Licensed Services. 

  

	 	1.8.	“Further Sublicense” means a sublicense granted by a Sublicensee to a third party, of any or all of the rights granted hereunder to such Sublicensee.
For the avoidance of doubt, a Further Sublicense is not, nor does it include, any Sublicense, and vice versa. 

  

	 	1.9.	“Further Sublicensee” means a party with which a Sublicensee has entered into a Further Sublicense. For the avoidance of doubt, a Further Sublicensee
is not, and does not include, any Sublicensee, and vice versa. 

  

	 	1.10.	“Have Made” and “Have Sold,” with respect to a Licensed Product, means to have such product made or sold by a third party during the
term of this Agreement. 

  

	 	1.11.	“IND” means Investigational New Drug application to be filed with the FDA, and reference to the submission of an IND means the submission to the FDA.

  

	 	1.12.	“Joint Venture” means any separate entity established pursuant to an agreement between a third party and Licensee and/or a Sublicensee under which the
separate entity manufactures, has made, uses, purchases, Sells, has Sold or acquires Licensed Products from Licensee or Sublicensee. 

  
 ***
INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED. 
  

					
		 	6	 	***_FivePrime

	 	1.13.	“Licensed Diagnostic Product” means a Licensed Product for use in an in vitro or in vivo reagent for human diagnostic and/or prognostic applications.

  

	 	1.14.	“Licensed Method” means any process, art or method the use or practice of which, in any given country, but for the license granted in this Agreement,
would infringe, or contribute to, or induce the infringement of, any of the Patent Rights were they issued at the time of the infringing activity in that country. 

 

	 	1.15.	“Licensed Product” means any kit, article of manufacture, composition of matter, material, compound, component, or product , including, without
limitation, one used in or made by practicing a Licensed Method, the manufacture, use, Sale, offer for Sale or import of which, in any given country, but for the license granted in this Agreement, would infringe, or contribute to, or induce the
infringement of, any of Patent Rights were it issued at the time of the infringing activity in that country. 

  

	 	1.16.	“Licensed Therapeutic Product” means a Licensed Product used to prevent, treat, or cure one or more diseases or conditions. 

 

	 	1.17.	“Licensee” means Five Prime Therapeutics Inc. and those of its Affiliates with which it has entered into an Affiliation Agreement.

  

	 	1.18.	“Marketing Approval” means the approvals, licenses, registrations or authorizations of any national, supra-national regional, state or local regulatory
agency, department, bureau, commission, council or other governmental entity, necessary for the commercial distribution, use or Sale of a Licensed Product in a given jurisdiction or a country. 

 

	 	1.19.	“Net Invoice Price” means the gross invoice price charged by Licensee, a Sublicensee or a Further Sublicensee for a Licensed Product or a Combination
Product (in its entirety) less the items specified in Paragraphs 1.19.1-1.19.6, to the extent that such items actually pertain to the disposition of such Licensed Product or Combination Product and are separately billed: 

  
 ***
INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED. 
  

					
		 	7	 	***_FivePrime

 1.19.1. Allowances or discounts actually granted or repaid to customers
for rejections, returns, prompt payment, volume purchases, price adjustments or billing errors; 
 1.19.2.
Freight, handling, transport packing, postage, transportation and insurance charges associated with transportation; 
 1.19.3. Taxes, including Deductible Value Added Tax, tariffs or import/export duties based on Sales when included in the gross invoice price, but excluding value-added taxes other than Deductible Value
Added Tax or taxes assessed on income derived from Sales. “Deductible Value Added Tax” means value added tax only to the extent that such value added tax is actually incurred and is not reimbursable, refundable or creditable under
the tax authority of any country; 
 1.19.4. Those discounts and rebates that are part of a formulary program
and are paid or credited to customers, third-party payers, healthcare systems, or administrators for a Licensed Product when included in such formulary program, as permitted by 42 U.S.C. § 1320a-7b; 

1.19.5. Other rebates and discounts paid or credited pursuant to applicable law; and 

1.19.6. Allowances for Uncollectible Amounts. For purposes of this Paragraph 1.19.6, “Uncollectible
Amounts” means amounts owed and unpaid to Licensee or a Sublicensee for previously Sold Licensed Products, which Licensee or the Sublicensee has attempted to collect, using efforts at least as diligent as those efforts that Licensee or the
Sublicensee (as applicable) uses in attempting to collect other overdue debts. 
  

	 	1.20.	“Net Sales” means: 

 1.20.1. Except in the instances described in Paragraphs 1.20.2, 1.20.3 and 1.20.4, the Net Invoice Price; 

  
 ***
INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED. 
  

					
		 	8	 	***_FivePrime

 1.20.2. For any Relationship-Influenced Sale, Net Sales shall be based on
the Net Invoice Price at which the Purchaser resells the Licensed Products that were the subject of the Sale; 

1.20.3. In those instances where Licensed Product is not Sold but is otherwise exploited, or where consideration
received for Licensed Product is other than money, Net Sales shall be equivalent to the gross invoice price charged for products of the same or similar kind and quality, Sold in similar quantities, currently being offered for Sale by the Licensee,
or any Sublicensee or Further Sublicensee, or if not currently being offered for Sale by the Licensee or any Sublicensee or Further Sublicensee, by other manufacturers, less the items specified in Paragraphs 1.19.1-1.19.6. Where such products are
not currently Sold or offered for Sale by anyone, Net Sales shall be the Licensee’s and/or any Sublicensee’s or Further Sublicensee’s cost of manufacture of the relevant Licensed Product, determined according to generally accepted
accounting principles (“GAAP”), plus *** percent (***%). 
 1.20.4. In those instances
where Licensee or any Sublicensee acquires a Licensed Product and then subsequently Sells it, Net Sales shall mean the Net Invoice Price on the Sale of such Licensed Product by Licensee, a Sublicensee or a Further Sublicensee, with the resulting
Royalty due to The Regents subject to a deduction for any Royalties paid to The Regents on account of any earlier Sale of such Licensed Product; 
 1.20.5. For a Combination Product, Net Sales shall be calculated as: 
  

	 	(a)	(A/(A+B)) x (Net Sales, calculated without regard to this formula, of the Licensed Product that is included in the Combination Product), where:

  

	 	(b)	“A” is the total of Net Sales of each Licensed Product contained included in the Combination Product, if Sold separately; and 

  
 ***
INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED. 
  

					
		 	9	 	***_FivePrime

	 	(c)	“B” is the total of net sales (as calculated pursuant to Paragraphs 1.19 and 1.20) of each Combination Product Component included in the Combination Product,
if Sold separately. (If the Combination Product Component(s) is not being sold or offered for sale separately by Licensee or a Sublicensee, the price of such component(s) shall be based on the price at which products of the same or similar kind and
quality, sold in similar quantities, are then being offered for sale by other manufacturers. If the Combination Product Component(s) are not being sold or offered for sale separately at all, then the price of such components shall be equal to
Licensee’s or Sublicensee’s cost of manufacture of the Licensed Product, determined according to generally accepted accounting principles, plus *** percent (***%) 

 

	 	(d)	Notwithstanding anything to the contrary in this Paragraph 1.20.5, in no event shall Net Sales of a Combination Product be less than *** percent (***%) of
Net Sales of the Licensed Product included in the Combination Product, calculated without regard to this formula. 

 1.20.6. Notwithstanding the foregoing, transfers or other dispositions of Licensed Products for no consideration or for consideration at or below the cost of manufacture thereof, in commercially
reasonable quantities, for charitable or benevolent (e.g., for use in investigator-initiated studies by not-for-profit entities), promotional, preclinical, clinical, manufacturing scale-up, regulatory or governmental (i.e., required by a
governmental authority to be supplied to a governmental authority for use by such governmental authority) purposes, and the like, shall not be included in the calculation of Net Invoice Price or Net Sales. Licensee shall promptly notify The Regents
of all Sales it believes are within the scope of this Paragraph 1.20.6. In any case in which it is not clear if a transfer or other disposition of Licensed Products falls within the scope of this Paragraph 1.20.6, the parties will promptly confer
and attempt to resolve the matter in good faith. 

  
 ***
INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED. 
  

					
		 	10	 	***_FivePrime

	 	1.21.	“New Developments” means inventions, or claims to inventions, which constitute advancements, developments or improvements, whether or not patentable
and whether or not the subject of any patent application, which are not sufficiently supported by the specification of a previously-filed patent or patent application within the Patent Rights to be entitled to the priority date of the
previously-filed patent or patent application. 

  

	 	1.22.	“Novartis Patents” means those Patent Rights identified in Part 2 of Appendix A. 

 

	 	1.23.	“Patent Prosecution Costs” means the cost of preparing, filing, prosecuting, and maintaining the Patent Rights. 

 

	 	1.24.	“Patent Rights” means the Valid Claims of the United States and foreign patents and patent applications listed in Appendix A, which is attached hereto
and incorporated herein by reference, to the extent assigned to or otherwise obtained by The Regents, and any reissues, re-examinations, continuations, divisions, and continuation-in-part patents and applications (but only those Valid Claims in the
continuation-in-part applications/patents that are entirely supported in the specification and entitled to the priority date of the parent application). Patent Rights do not include any rights in or to New Developments. 

 

	 	1.25.	“Related Party” means a corporation, firm, other entity or individual with which Licensee or any Sublicensee or Further Sublicensee (or any of their
respective stockholders, subsidiaries or Affiliates) has any agreement, understanding or arrangement (e.g., but not by way of limitation, an option to purchase stock or other equity interest, or an arrangement involving a division of revenue,
profits, discounts, rebates or allowances) unrelated to the Sale of Licensed Products, that causes Licensee or such Sublicensee or Further Sublicensee to extend to such corporation, firm, other entity or individual lower prices for such Licensed
Products, in similar quantities, than those prices charged to others without such an agreement, understanding or arrangement with Licensee or such Sublicensee or Further Sublicensee. 

  
 ***
INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED. 
  

					
		 	11	 	***_FivePrime

	 	1.26.	“Phase 1 Clinical Trials,” “Phase 2 Clinical Trials” and “Phase 3 Clinical Trials” have the same meanings as those
terms have in Part 21 of the United States Code of Federal Regulations §312.21, or foreign equivalents thereof. For the avoidance of doubt, `initiation’ of Phase 1, Phase 2 or Phase 3 trials (or the ‘entry’ of a Licensed Product
into such trials) occurs at the time of dosing of the first human subject in the first Phase 1, Phase 2 or Phase 3 trial (as applicable), in any given Therapeutic Area. 

 

	 	1.27.	“Relationship-Influenced Sale” means a Sale of a Licensed Product between (a) FivePrime and its Affiliate, a Joint Venture, a Related Party or a
Sublicensee, (b) a Sublicensee and its Affiliate or (c) a Further Sublicensee and its Affiliates. 

  

	 	1.28.	“Royalties” means the royalties to be paid by Licensee to The Regents pursuant to Paragraph 8.1. 

 

	 	1.29.	“Sale” means the act of selling, leasing or otherwise transferring, providing, furnishing for use or exploiting, in exchange for any consideration.
Correspondingly, “Sell” means to make or cause to be made a Sale and “Sold” means to Have Made or caused to be made a Sale. 

 

	 	1.30.	“Sublicense” means a sublicense granted by Licensee to a third party (including a Joint Venture) of any or all of the Patent Rights.

  

	 	1.31.	“Sublicensed Product” means any Licensed Product that is developed, made, used, Sold, offered for Sale or imported by or on behalf of a Sublicensee,
whether Sold separately or as part of a Combination Product. 

  

	 	1.32.	“Sublicensee” means the party with which Licensee has entered into a Sublicense. “Sublicense Fees” is defined in Paragraph 7.1.

  
 ***
INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED. 
  

					
		 	12	 	***_FivePrime

	 	1.33.	“Therapeutic Area” means (a) all cancers and (b) any other group of related indications, such as “all ocular diseases,” “all
skin diseases” or “all cardiovascular diseases,” excluding those caused by cancer. For example, prostate cancer, breast cancer and melanoma would fall within one therapeutic area (cancer), while atopic dermatitis, eczema and hives -
but not melanoma - would fall within another related area (skin disease). 

  

	 	1.34.	“UC Patents” means those Patent Rights identified in Part 1 of Appendix A. 

 

	 	1.35.	“Valid Claim” means a claim of a patent or patent application in any country that (a) has not expired; (b) has not been disclaimed;
(c) has not been cancelled or superseded, or if cancelled or superseded, has been reinstated; and (d) has not been revoked, held invalid, or otherwise declared unenforceable or not allowable by a tribunal or patent authority of competent
jurisdiction over such claim in such country from which no further appeal has or may be taken. 

  

	2.	GRANTS 

  

	 	2.1.	Subject to the limitations and other terms and conditions set forth in this Agreement, including those set forth in Paragraphs 2.4 and 2.5, The Regents hereby grants to
Licensee (a) exclusive licenses under the UC Patents, and (b) exclusive sublicenses under its rights to the Novartis Patents, which were obtained pursuant to a license agreement between The Regents and Novartis attached to this Agreement
as an Appendix C, to make, Have Made, use, Sell, Have Sold, offer for Sale, and import Licensed Products and to practice the Licensed Method in the United States and in other countries where The Regents may lawfully grant such licenses, only in the
Field of Use. 

  

	 	2.2.	The Regents represents that (a) Appendix C is a true and correct copy of the aforementioned license agreement between The Regents and Novartis and (b) said
license is in good standing. 

  

	 	2.3.	Licensee agrees that (a) the licenses granted to it hereunder to the UC Patents and (b) the sublicenses granted to it hereunder to the Novartis Patents, are
of equal value. 

  
 ***
INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED. 
  

					
		 	13	 	***_FivePrime

	 	2.4.	The licenses under the UC Patents will be subject to the overriding obligations to the United States Government including those set forth in 35 U.S.C. §200-212 and
applicable governmental implementing regulations and the obligation to report on utilization of the Invention set forth in 37 CFR §401.14(h). 

  

	 	2.5.	The licenses under the UC Patents also will be subject to the paid-up, non-exclusive, irrevocable licenses reserved by HHMI to make and use the Invention for its
research purposes. Such licenses reserved by HHMI specified in the recitals and the immediately prior sentence do not include the right to sublicense others. Moreover, the licenses granted to Licensee hereunder also are subject to the National
Institutes of Health “Principles and Guidelines for Recipients of NIH Research Grants and Contracts on Obtaining and Disseminating Biomedical Research Resources” set forth in 64F.R. 72090 (Dec. 23, 1999) and HHMI’s statement of policy
on research tools. HHMI’s policy can be found at www.hmi.org/about/oge/downloads/4237105.pdf. 

  

	 	2.6.	The Regents reserves and retains the right (and the rights granted to Licensee in this Agreement shall be limited accordingly) to make, use and practice the Invention
and any technology relating to the Invention and to make and use any products and to practice any processes that are the subject of the Patent Rights (and to grant any of the foregoing rights to other educational and non-profit institutions) solely
for educational and research purposes, including without limitation, any sponsored research performed for or on behalf of commercial entities and including publication and other communication of any research results. For the avoidance of doubt, to
the extent the Invention and any technology relating thereto is not the subject of the exclusive license granted hereunder, The Regents shall be free to make, use, Sell, offer to Sell, import, practice and otherwise commercialize and exploit
(including transferring to, licensing, or having practiced by third parties) for any purpose whatsoever and in its sole discretion, such Invention, technology and any products or processes that are the subject of the Patent Rights.

  
 ***
INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED. 
  

					
		 	14	 	***_FivePrime

	 	2.7.	Because the Invention was made under funding provided by the United States Government, Licensed Products Sold by Licensee, Sublicensees or Further Sublicensees in the
United States will be substantially manufactured in the United States, as required under applicable federal regulations. 

  

	3.	AFFILIATION AGREEMENTS 

  

	 	3.1.	In order for an Affiliate of FivePrime to be considered a Licensee, such Affiliate shall be subject to a written Affiliation Agreement that shall include terms and
conditions that are consistent with and not in violation of any applicable terms, conditions, obligations, restrictions or other covenants of this Agreement that protect or benefit The Regents’ (and, if applicable, the U.S. Government’s
and other sponsors’) rights and interests. FivePrime shall attach a copy of this Agreement to each Affiliation Agreement, provided that FivePrime may redact from such copy economic terms and technical information that does not relate to the
Affiliation Agreement, and shall specify in the Affiliation Agreement that the Affiliate must comply with all applicable terms of this Agreement, as if the Affiliate were FivePrime. Within *** days of execution of any Affiliation Agreement,
FivePrime shall (a) provide The Regents with a copy of the Affiliation Agreement, provided that FivePrime may redact from such copy technical information and economic terms that do not relate to the Patent Rights, and (b) notify The
Regents of the identity of and contact information for such Affiliate. 

  

	 	3.2.	 For the purposes of this Agreement, the operations of all Affiliates who have entered into an Affiliation Agreement shall be deemed to be the
operations of FivePrime, for which FivePrime shall be responsible. FivePrime will collect from all Affiliates who have entered into an Affiliation Agreement and will pay to The Regents all fees, payments, and royalties that are due to The Regents
hereunder. FivePrime will guarantee all monies due The Regents from all Affiliates who have entered into an Affiliation Agreement. For clarity, if an Affiliation Agreement contains a provision for payment of

  
 ***
INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED. 
  

					
		 	15	 	***_FivePrime

	 	 
royalties in an amount that is less than the Royalties required to be paid under Paragraph 8.1, then FivePrime will pay to The Regents the difference between such lesser amount and the relevant
Royalties. FivePrime will either (a) include in its Progress Reports and Quarterly Reports (defined below) to The Regents the activities of, and Royalties due from all Affiliates who have entered into an Affiliation Agreement or
(b) require any Affiliates who have entered into an Affiliation Agreement whose activities are not covered in FivePrime’s Progress Reports and Quarterly Reports to provide FivePrime with copies of progress reports and quarterly reports
that are consistent with the provisions herein, and provide copies of such reports to The Regents. 

  

	 	3.3.	If FivePrime contemplates entering into an agreement with an Affiliate of FivePrime under which it would grant such Affiliate a license to patent rights other than the
Patent Rights (“FivePrime’s Patent Rights”), and believes, in good faith, that such Affiliate would infringe any of the Patent Rights in practicing FivePrime’s Patent Rights, then FivePrime will not enter into such
agreement with the Affiliate but will enter into an Affiliation Agreement instead. 

  

	 	3.4.	Upon expiration or termination of this Agreement for any reason, all Affiliation Agreements shall automatically terminate, unless The Regents, at its sole discretion,
agrees in writing to an assignment to The Regents of any such Affiliation Agreement. The Regents shall not be bound to any duties under such an assigned Affiliation Agreement beyond The Regents’ duties under this Agreement. Such an assignment
will include a modification of the Affiliation Agreement at issue that requires payment of Royalties directly to The Regents by the Affiliate, as if it were FivePrime, at a rate that is no lower than the rates set forth in Paragraph 8.1, in
accordance with Article 5 (Payment Terms). 

  
 ***
INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED. 
  

					
		 	16	 	***_FivePrime

	4.	RIGHT TO GRANT SUBLICENSES 

  

	 	4.1.	The Regents also grants to Licensee the right to sublicense to third parties the Patent Rights, with no right to grant further sublicenses except as provided below, as
long as Licensee has exclusive rights thereto under this Agreement. Each Sublicensee must be subject to a written sublicense agreement as specified in Paragraph 4.3. For the avoidance of doubt, Licensee’s Joint Ventures shall have no licenses
under this Agreement unless such Joint Ventures are granted Sublicenses. For the purposes of this Agreement, the operations of all Sublicensees shall be deemed to be the operations of Licensee, for which Licensee shall be responsible.

  

	 	4.2.	Under the terms of each Sublicense, the Sublicensee thereunder shall have the limited right (as described below) to grant Further Sublicenses. A Further Sublicense may
only be granted to the extent that the Sublicensee deems it to be reasonably needed for the development, seeking of Marketing Approval or other regulatory approval (including conducting pre-clinical and clinical trials), manufacture and/or
commercialization of Sublicensed Product(s), and/or the maximization of Sales of such product(s). 

  

	 	4.3.	Each Sublicensee and its permitted Further Sublicensees shall be subject to a written sublicense agreement that shall be consistent with and not in violation of any
applicable terms, conditions, obligations, restrictions or other covenants of this Agreement that protect or benefit The Regents’ (and, if applicable, the U.S. Government’s and other sponsors’) rights and interests. Licensee shall
attach a copy of this Agreement to each Sublicense, provided that Licensee may redact from such copy economic teens and technical information that does not relate to the Sublicensed Patent Rights, and shall specify in the Sublicense that the
Sublicensee must comply with all applicable terms of this Agreement, as if the Sublicensee were Licensee and Licensee were The Regents hereunder. Within *** days of the issuance of any Sublicense, Licensee shall provide The Regents with a
copy of the Sublicense, provided that Licensee may redact from such copy technical information that does not relate to the Patent Rights, and economic terms that do not relate to the grant of the Sublicense under the Patent Rights.

  
 ***
INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED. 
  

					
		 	17	 	***_FivePrime

	 	4.4.	Licensee will collect from Sublicensees and will pay to The Regents all fees, payments, and royalties thereunder that are due to The Regents. Licensee will guarantee
all monies due The Regents from Sublicensees. For clarity, if a Sublicense contains a provision for payment of royalties in an amount that is less than the Royalties required to be paid under Paragraph 8.1, then Licensee will pay to The Regents the
difference between such lesser amount and the relevant Royalties. Licensee will require Sublicensees to provide it with copies of progress reports and quarterly reports that are consistent with the provisions herein and Licensee will collect and
deliver copies of such reports to The Regents. 

  

	 	4.5.	If Licensee contemplates granting a license to patent rights other than the Patent Rights (“Licensee’s Patent Rights”) and believes, in good
faith, that the recipient of such license would infringe any of the Patent Rights in practicing such Licensee’s Patent Rights, then Licensee will not grant a license to Licensee’s Patent Rights without concurrently granting a Sublicense
under the Patent Rights. 

  

	 	4.6.	Upon expiration or termination of this Agreement for any reason, all Sublicenses and Further Sublicenses shall automatically terminate, unless The Regents, at its sole
discretion, agrees in writing to an assignment to The Regents of any such Sublicense. The Regents shall not be bound to any duties under such an assigned Sublicense beyond The Regents’ duties under this Agreement. Such an assignment will
include a modification of the Sublicense at issue that requires payment of Royalties directly to The Regents by the Sublicensee as if it were Licensee at a rate that is no lower than the rates set forth in Paragraph 8.1 in accordance with Article 6
(Payment Terms). 

  
 ***
INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED. 
  

					
		 	18	 	***_FivePrime

	5.	PAYMENT TERMS 

  

	 	5.1.	Royalties will accrue in each country in which a Licensed Product, but for the license, infringes any of the existing Patent Rights, until the earlier of
(a) expiration of the last to expire of such of Patent Rights in such country or (b) cessation of Sale of the Licensed Product in such country. Sublicense Fees shall become payable to The Regents within *** days of the date that the
Attributed Income on which they are based is received by Licensee. 

  

	 	5.2.	Licensee will pay to The Regents all Royalties to The Regents, on a calendar quarterly basis, on or before each March 31 (for Royalties received during the quarter
ending December 31), June 30 (for Royalties received during the quarter ending March 31), September 30 (for Royalties received during the quarter ending June 30) and December 31 (for Royalties received during
the quarter ending September 30) of each calendar year. All consideration due to The Regents will be payable in United States dollars by (a) check payable to “The Regents of the University of California,” or (b) wire
transfer to an account designated by The Regents, provided that Licensee shall be responsible for all bank or other transfer charges associated with such wire transfer. When Licensed Products are Sold for monies other than United States dollars, the
Royalties will first be determined in the foreign currency of the country in which such Licensed Products were Sold and then converted into equivalent United States dollars. The exchange rate will be the average exchange rate quoted in The Wall
Street Journal during the last *** days of the relevant reporting period. 

  

	 	5.3.	Sublicense Fees and Royalties due hereunder that accrue outside the United States may not be reduced by any taxes, fees or other charges imposed by the government of
such country, except for those taxes, fees and charges that may be deducted from Net Sales pursuant to Paragraphs 1.19 and 1.20. 

  
 ***
INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED. 
  

					
		 	19	 	***_FivePrime

	 	5.4.	Notwithstanding the provisions of Article 27 (Force Majeure), if at any time, legal restrictions prevent Licensee’s prompt remittance of Royalties owed on Net
Sales in a given country, the proceeds of which have been received by Licensee, then Licensee shall convert the amount owed to The Regents into United States dollars and will pay The Regents directly from another source of funds in order to remit
the entire amount owed to The Regents. 

  

	 	5.5.	In the event that any patent or claim thereof included within the Patent Rights is held invalid in a final decision by a court of competent jurisdiction and last resort
and from which no appeal has or can be taken, then all obligation to pay Royalties based on that patent or claim or any claim patentably indistinct therefrom will cease as of the date of final decision. Licensee will not, however, be relieved from
paying any Royalties that accrued before such final decision, and Licensee shall be obligated to pay the full amount of Royalties due hereunder with respect to the remaining Patent Rights. 

 

	 	5.6.	No Royalties will be collected by or paid hereunder to The Regents on Licensed Products Sold to the account of the United States Government as provided in the license
retained by the United States Government pursuant to 35 U.S.C. §§ 200-212. Licensee and Sublicensees will reduce the amount charged for Licensed Products Sold to the United States Government by an amount equal to the Royalty for such
Licensed Products that otherwise would be due to The Regents. Such reduction in Royalties will be in addition to any other reductions in price required by the United States Government. 

 

	 	5.7.	In the event that Royalties, Sublicense Fees, reimbursements for Patent Prosecution Costs or other monies owed to The Regents are not received by The Regents when due,
Licensee will pay The Regents interest at a rate of *** percent (***%) simple interest per annum. Such interest will be calculated from the date payment was due until actually received by The Regents. Such accrual of interest will be
in addition to, and not in lieu of, enforcement of any other rights of The Regents due to such late payment. 

  
 ***
INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED. 
  

					
		 	20	 	***_FivePrime

	6.	LICENSE ISSUE FEE 

  

	 	6.1.	Licensee shall pay to The Regents a license issue fee of *** dollars ($***) within *** days of the Effective Date. This fee is non-refundable,
non-cancelable and is not an advance or otherwise creditable against any Royalties or other payments required to be paid under the terms of this Agreement. 

 

	7.	PAYMENTS ON SUBLICENSES AND FURTHER SUBLICENSES 

  

	 	7.1.	Licensee will pay to The Regents the following non-refundable and non-creditable fees in connection with Sublicenses and Further Sublicenses, to the extent that
Licensee realizes direct income therefrom (jointly “Sublicense Fees”): 

 7.1.1.
*** percent (***%) of all Attributed Income for any such sublicenses executed prior to the initiation of the first animal study of a Licensed Product. 

7.1.2. *** percent (***%) of all Attributed Income for any such sublicenses executed after initiation of
the first animal study of a Licensed Product but prior to the filing of the first IND covering a Licensed Product. 
 7.1.3. *** percent (***%) of all Attributed Income for any such sublicenses executed after the filing of the first IND covering a Licensed Product but prior to initiation of the first Phase
1 Clinical Trial of a Licensed Product. 
 7.1.4. *** (***%) of all Attributed Income for any
such sublicenses executed after the filing of the first IND covering a Licensed Product but prior to initiation of the first Phase 2 Clinical Trial of a Licensed Product. 

7.1.5. *** percent (***%) of all Attributed Income for any such sublicenses executed at any time after the
initiation of the first Phase 2 Clinical Trial of a Licensed Product or thereafter. 
  

	 	7.2.	Notwithstanding the above, the minimum Sublicense Fee due to The Regents upon execution of any relevant Sublicense (but not upon execution of any Further Sublicense)
shall be *** dollars ($***). 

  
 ***
INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED. 
  

					
		 	21	 	***_FivePrime

	8.	ROYALTIES 

  

	 	8.1.	Licensee will also pay to The Regents a non-refundable and non-creditable Royalties of (a) *** percent (***%) of the Net Sales of each Licensed
Therapeutic Product and (b) one and *** percent (***%) of the Net Sales of each Licensed Diagnostic Product. For the avoidance of doubt, above Royalties are due on all Net Sales, whether made by Licensee, a Sublicensee or a
Further Sublicensee. 

  

	 	8.2.	In the event it becomes necessary for Licensee, a Sublicensee or Further Sublicensee to obtain a license to patent rights owned by a third party, and Licensee or the
Sublicensee or Further Sublicensee must pay royalties to that third party in order to make, Have Made, use, Sell or Have Sold a Licensed Product, or to practice a Licensed Method, then Licensee shall have the right to credit *** percent
(***%) of any payment made to such third party in order to obtain or maintain such license against up to *** percent (***%) of the Royalties payable to The Regents under Paragraph 8.1 on a going-forward basis. Notwithstanding
the foregoing, such right shall not apply to any payment for a third-party license required solely in connection with the manufacture, use or Sale of a Combination Product Component. 

 

	9.	MILESTONE PAYMENTS 

  

	 	9.1.	Upon reaching the following milestones based on activities by or on behalf of Licensee, or any Sublicensee or Further Sublicensee, Licensee will make one-time payments
to The Regents of each of the following non-refundable, non-creditable amounts: 

  

	 	9.1.1.	 For Licensed Therapeutic Product: 

  

	 	(a)	With respect to the first Licensed Therapeutic Product in each Therapeutic Area to reach the milestone recited below: 

 

	 	  (i)	*** dollars ($***) following initiation of the first Phase l Clinical Trial 

 

	 	 (ii)	*** dollars ($***) following initiation of the first Phase 3 Clinical Trial 

 

	 	(iii)	*** dollars ($***) following the grant of the first Marketing Approval 

  
 ***
INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED. 
  

					
		 	22	 	***_FivePrime

	 	(b)	With respect to the second Licensed Therapeutic Product, in each Therapeutic Area to be granted Marketing Approval: *** ($***) dollars following the first
grant of such Marketing Approval. 

 9.1.2. For Licensed Diagnostic Product: ***
dollars ($***) upon the grant of the first Marketing Approval. 
  

	 	9.2.	For the avoidance of doubt, each of the foregoing milestone payments will be payable regardless of whether the applicable milestone event has been achieved by a
Licensee, Sublicensee or Further Sublicensee. 

  

	 	9.3.	All milestone payments will be due to The Regents within *** days of the occurrence of the applicable milestone event. 

 

	10.	DUE DILIGENCE 

  

	 	10.1.	During the term of this Agreement, Licensee and/or Sublicensee(s) will use all Commercially Reasonable Efforts to proceed with the development, manufacture and Sale of
one or more Licensed Therapeutic Products and will earnestly and diligently market such product(s) after receipt of Marketing Approval thereof. Such efforts shall include employing or engaging, at all relevant times, the equivalent of at least
*** full-time-employees (which equivalents may be either employees or contractors of Licensee or a Sublicensee), to work on advancing Licensed Product(s), through each stage necessary to market the product commercially (i.e., the stages of
(a) research, (b) preclinical testing, (c) preparation and filing of INDs, (d) clinical trials, (e) applications for Marketing Approval, etc.) Each such employee or contractor shall have the skills and training necessary to
advance the relevant Licensed Product through the stage in which such employee or contractor is involved. 

  

	 	10.2.	 If Licensee, itself or through its Sublicensees, is unable to comply with Paragraph 10.1, The Regents may notify Licensee, in writing, of the
deficiency and of The Regents’ right, pursuant to Paragraph 10.3, to terminate or reduce the licenses granted hereunder 

  
 ***
INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED. 
  

					
		 	23	 	***_FivePrime

	 	 
(a “Deficiency Notice”). Upon request by Licensee made within *** days of receipt of such a notice, The Regents promptly shall meet with Licensee and shall discuss in good
faith the reasons for the deficiency and any reasonable alternative criteria that Licensee might be permitted to meet in order to satisfy its Due Diligence obligations. 

 

	 	10.3.	Unless the parties have otherwise agreed in writing within *** days of Licensee’s receipt of a Deficiency Notice, The Regents shall have the right and the
option to terminate this Agreement or to reduce the exclusive license granted hereunder, in whole or in part, to a nonexclusive license, immediately upon notice to Licensee, unless Licensee has cured the relevant deficiency and provided The Regents
with tangible evidence thereof, satisfactory to The Regents, within *** days of Licensee’s receipt of the Deficiency Notice. The right of The Regents to terminate or reduce the license shall supersede the rights granted in Article 2
(Grants). 

  

	11.	PROGRESS AND ROYALTY REPORTS 

  

	 	11.1.	Beginning on December 31, 2006, and annually thereafter, Licensee will submit to The Regents a written progress report covering Licensee’s and any
Sublicensees’ or Further Sublicensees’) activities during the twelve (12) month period ending September 30 of the year in which the progress report is due, related to the development, testing, manufacture and/or marketing of
Licensed Products, including the activities required and undertaken in order to meet the diligence requirements set forth in Paragraph 10.1 (“Progress Reports”). 

 

	 	11.2.	Progress Reports shall be required for each Licensed Product under development, until the first Sale of that Licensed Product occurs in the United States, and shall be
required again if after such Licensed Product has been Sold, Sales thereof are suspended or discontinued, unless and until further development or Sale of such product is abandoned. 

  
 ***
INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED. 
  

					
		 	24	 	***_FivePrime

	 	11.3.	Progress Reports shall include, without limitation, a summary of the following topics sufficient to enable The Regents to determine (a) the progress of the
development of Licensed Products and (b) whether or not Licensee has met the diligence obligations set forth in Paragraph 10.1. 

 11.3.1. ***; 
 11.3.2. ***; 

11.3.3. ***; 

11.3.4. ***; and 
 11.3.5. ***. 
  

	 	11.4.	Progress Reports also shall identify (a) any entities that have become Affiliates of FivePrime; (b) any Sublicensee Fees received during the year; and
(c) the information specified in Paragraph 3.2. 

  

	 	11.5.	The failure of Licensee to submit a Progress Report or update to The Regents within *** days of its due date shall constitute a default pursuant to Article 14
(Termination by The Regents). If this Agreement is terminated or expires before any Licensed Product has been Sold, then a final Progress Report covering the period between submission of the previous Progress Report and the termination or expiration
date must be submitted to The Regents within *** days of termination or expiration. 

  

	 	11.6.	Licensee shall have a continuing responsibility to keep The Regents informed of the business entity status (small business entity status or large business entity status
as defined by the United States Patent and Trademark Office) of itself, any Affiliates who have entered into an Affiliation Agreement ,Sublicensees and Further Sublicensees. Licensee will notify The Regents of any change in Licensee’s status
within *** days of the change. Licensee will require in each Sublicense that the Sublicensee notify Licensee of any change in such Sublicensee’s business status within *** days of the change, and Licensee shall notify The Regents
of such changes within *** days of learning of it. 

  
 ***
INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED. 
  

					
		 	25	 	***_FivePrime

	 	11.7.	Following the first Sale of a Licensed Product, Licensee will provide The Regents, along with the payments due under Paragraph 5.2, quarterly reports of the Royalties
owed to The Regents (“Quarterly Reports”). Each such report shall be due on the date the Royalties reported therein are due and shall cover the period for which such Royalties are due, pursuant to Paragraph 5.2, and will, at a
minimum, show: 

  

	 	11.7.1.	The gross invoice prices and Net Sales of Licensed Products Sold (itemizing the applicable gross proceeds and any deductions therefrom), and any applicable Attributed
Income (itemizing the applicable gross proceeds and any deductions therefrom) received; 

  

	 	11.7.2.	The quantity of each type of Licensed Product Sold; 

  

	 	11.7.3.	The country in which each Licensed Product was Sold; 

  

	 	11.7.4.	Royalties payable (in United States dollars), 

  

	 	11.7.5.	The method used to calculate the Royalties; 

  

	 	11.7.6.	The exchange rates used, if any; 

  

	 	11.7.7.	Any other information, Licensee believes, in good faith, is reasonably necessary to explain its calculation hereunder. 

 

	 	11.8.	If no Royalties are due during any reporting period, then a statement to that effect must be provided by Licensee in the immediately subsequent Quarterly Report.

  

	12.	BOOKS AND RECORDS 

  

	 	12.1.	 Licensee will keep accurate books and records showing all Licensed Products under development, manufactured, used, offered for Sale, imported, and
Sold; all Net Sales; all Attributed Income; any other amounts payable hereunder; and all Sublicenses. Such books and records will be preserved for at least *** years after the date of the payment to which they pertain and upon request by The
Regents, will be opened once per calendar year, for inspection by a certified public accountant selected by The Regents and reasonably acceptable to Licensee, at a mutually agreed upon time during normal

  
 ***
INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED. 
  

					
		 	26	 	***_FivePrime

	 	 
business hours, for the purpose of determining the accuracy of such books and records and assessing Licensee’s compliance with the terms of this Agreement. Such accountant shall be under a
duty of confidentiality to Licensee to reveal to The Regents only that information directly relevant to the accuracy of such books and records and/or to Licensee’s compliance with the terms of this Agreement. 

 

	 	12.2.	The Regents shall pay the fees and expenses of such examination. If, however, an error of more than *** percent (***%) of the total Royalties due for any
year is discovered in any examination, then Licensee shall bear the fees and expenses of such examination and shall remit such underpayment to The Regents within *** days of receipt of the inspection results. 

 

	13.	LIFE OF THE AGREEMENT 

  

	 	13.1.	Unless otherwise terminated (a) by operation of law, (b) as provided in Paragraph 13.2 or (c) by acts of the parties in accordance with the terms of this
Agreement, this Agreement will remain in effect from the Effective Date until the expiration or abandonment of the last to expire of the Patent Rights then licensed to Licensee hereunder. 

 

	 	13.2.	This Agreement will automatically terminate without the obligation to provide notice as set forth in Article 14 (Termination By The Regents) upon the filing of a
petition for relief under the United States Bankruptcy Code by or against Licensee as a debtor or alleged debtor, provided that if such petition is dismissed within *** days, this Agreement and all licenses granted hereunder shall be
reinstated as if no termination had occurred. 

  

	 	13.3.	Any termination or expiration of this Agreement will not affect the rights and obligations set forth in the following Paragraphs or Articles: 

 

			
	 Article 1
	    	Definitions
	 Paragraph 5.7
	    	Late Payments

  
 ***
INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED. 
  

					
		 	27	 	***_FivePrime

			
	 Article 6
	  	License Issue Fee
	 Article 7
	  	Payments on Sublicenses and Further Sublicenses
	 Article 8.1
	  	Royalties
	 Article 12
	  	Books and Records
	 Article 13
	  	Life of the Agreement
	 Article 16
	  	Disposition of Licensed Products upon Termination or Expiration
	 Article 17
	  	Use of Names and Trademarks
	 Article 18
	  	Limited Warranty
	 Article 19
	  	Limitations of Liability
	 Paragraphs 20.4 and 20.6
	  	Patent Prosecution and Maintenance
	 Article 23
	  	Indemnification
	 Article 24
	  	Notices
	 Article 28
	  	Governing Laws; Venue; Attorneys’ Fees
	 Article 31
	  	Confidentiality
	 Paragraph 32.5
	  	Invalidity of Agreement
	 Paragraph 32.8
	  	HHMI Third-Party Beneficiary Status

  

	 	13.4.	The termination or expiration of this Agreement will not relieve Licensee of its obligation to pay any fees, Royalties or other payments owed to The Regents at the time
of such termination or expiration and will not impair any accrued right of The Regents, including the right to receive Royalties in accordance with Article 8 (Royalties). 

 

	 	13.5.	In the event of early termination of this Agreement, The Regents shall refund to Licensee any Patent Prosecution Costs paid by Licensee that The Regents may collect
from a later licensee of any Patent Rights. 

  

	14.	TERMINATION BY THE REGENTS 

 If Licensee fails to
perform or violates any material term or covenant of this Agreement, then The Regents may give written notice of such default to Licensee. If Licensee fails to repair such default within *** days after the effective date of such notice, then
The Regents will have the right to immediately terminate this Agreement and its licenses, by a written notice of termination of this Agreement (a “Notice of Termination”) to Licensee. 

  
 ***
INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED. 
  

					
		 	28	 	***_FivePrime

	15.	TERMINATION BY LICENSEE 

 Licensee may at any
time terminate this Agreement in its entirety by providing a Notice of Termination to the Regents, or to terminate the licenses under Patent Rights on a country-by-country basis, by providing a written notice of such termination to The Regents.
Termination of this Agreement in its entirety (but not termination of fewer than all Patent Rights, which termination is subject to Paragraph 20.7) will be effective *** days from the effective date of such notice. 

 

	16.	DISPOSITION OF LICENSED PRODUCTS UPON TERMINATION OR EXPIRATION 

  

	 	16.1.	Within a period of *** days after the effective date of any termination of this Agreement, Licensee, Sublicensees and any Further Sublicensees shall be entitled
to dispose of all previously made or partially made Licensed Products, but no more, subject to the terms of this Agreement. Licensee, Sublicensees and any Further Sublicensees may not otherwise make, Have Made, Sell, Have Sold, offer for Sale or
import Licensed Products or practice the Licensed Method, pursuant to the license granted hereunder, after the date of termination. 

  

	 	16.2.	If applicable Patent Rights exist at the time of any manufacture, Sale, offer for Sale, or import of a Licensed Product, then Royalties shall be paid at the times
provided herein and Quarterly reports shall be rendered in connection therewith, notwithstanding the absence of applicable Patent Rights with respect to such Licensed Product at any later time. 

 

	17.	USE OF NAMES AND TRADEMARKS 

  

	 	17.1.	 (a) Nothing contained in this Agreement will be construed as conferring any right to either party to use in advertising, publicity or other promotional
activities any name, trade name, trademark or other designation of the other party (including a contraction, abbreviation or simulation of any of the foregoing, except as provided in Paragraph

  
 ***
INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED. 
  

					
		 	29	 	***_FivePrime

	 	 
17.2). (b) unless required by law or consented to in writing by Executive Director, Office of Technology Transfer of The Regents, the use by Licensee of the name “The Regents of the
University of California” or the name of any campus of the University of California in advertising, publicity or other promotional activities is prohibited. 

 

	 	17.2.	Notwithstanding Paragraph 17.1(a), without Licensee’s consent, (a) case-by-case, The Regents may list Licensee’s name as a licensee of technology from
The Regents, provided that the relevant technology is not further identified, and (b) Licensee may disclose the names listed in Paragraph 17.1(b) in connection with information permitted to be disclosed under Paragraph 31.2, subject to the
terms and conditions thereof. Licensee may not use the name of HHMI or of any HHMI employees (including any of the Inventors) in a manner that reasonably could constitute an endorsement of a commercial product; but that use for other put-poses, even if commercially motivated, is permitted provided that
(a) the use is limited to accurately reporting factual events or occurrences, and (b) any reference to the name of HHMI or any HHMI employees in press releases or similar materials intended for public release is approved by HHMI in
advance. 

  

	18.	LIMITED WARRANTY 

  

	 	18.1.	The Regents warrants to Licensee that it has the lawful right to grant this license. 

 

	 	18.2.	Except as expressly set forth in this Agreement, the licenses granted hereunder and the associated Invention and Patent Rights are provided by The Regents WITHOUT
WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR ANY OTHER WARRANTY OF ANY KIND, EXPRESS OR IMPLIED. THE REGENTS MAKES NO EXPRESS OR IMPLIED REPRESENTATION OR WARRANTY THAT THE INVENTION, PATENT RIGHTS, ANY LICENSED PRODUCT OR ANY
LICENSED METHOD WILL NOT INFRINGE ANY PATENT COPYRIGHT, TRADEMARK OR OTHER RIGHTS. 

  
 ***
INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED. 
  

					
		 	30	 	***_FivePrime

	 	18.3.	This Agreement does not: 

 18.3.1. Express or imply a warranty or representation as to the validity, enforceability, or scope of any Patent Rights; 

18.3.2. Express or imply a warranty or representation that anything made, used, Sold, offered for Sale or imported or
otherwise exploited under any license granted in this Agreement is or will be free from infringement of patents, copyrights, or other rights of third parties; 
 18.3.3. Obligate The Regents to bring or prosecute actions or suits against third parties for patent infringement, except as provided in Article 22 (Patent Infringement); 

18.3.4. Confer by implication, estoppel or otherwise any license or rights under any patents or other rights of The
Regents other than the Patent Rights, regardless of whether such patents are dominant or subordinate to the Patent Rights; 
 18.3.5. Obligate The Regents to furnish any New Developments, know-how, technology or information not provided in Patent Rights; or 

18.3.6. Obligate The Regents to update the technology in Patent Rights. 

 

	19.	LIMITATIONS OF LIABILITY 

 EXCEPT FOR
LICENSEE’S DUTY TO INDEMNIFY UNDER ARTICLE 23, NEITHER PARTY SHALL BE LIABLE FOR ANY LOST PROFITS, COSTS OF PROCURING SUBSTITUTE GOODS OR SERVICES, LOST BUSINESS, ENHANCED DAMAGES FOR INTELLECTUAL PROPERTY INFRINGEMENT OR ANY INDIRECT,
INCIDENTAL, CONSEQUENTIAL, PUNITIVE OR OTHER SPECIAL DAMAGES SUFFERED BY THE OTHER PARTY ARISING OUT OF OR RELATED TO THIS AGREEMENT FOR ANY CAUSE OF ACTION OF ANY KIND, INCLUDING TORT, CONTRACT, NEGLIGENCE, STRICT LIABILITY AND BREACH OF WARRANTY
EVEN IF THE OTHER PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES. NOR SHALL THE REGENTS BE LIABLE FOR ANY SUCH DAMAGES SUFFERED BY SUBLICENSEES, JOINT VENTURES OR AFFILIATES. 

  
 ***
INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED. 
  

					
		 	31	 	***_FivePrime

	20.	PATENT PROSECUTION AND MAINTENANCE 

  

	 	20.1.	As long as Licensee has paid Patent Prosecution Costs as provided in this Article 20 (Patent Prosecution and Maintenance), The Regents will diligently prosecute and
maintain all patents and patent applications comprising the Patent Rights using counsel of its choice. The Regents’ counsel will take instructions only from The Regents. Upon Licensee’s written instructions, The Regents will promptly
instruct its counsel to provide Licensee, at Licensee’s expense, with copies of all correspondence between The Regents and their counsel and all other documentation, past and present, relevant to the Patent Rights, so that Licensee will be
fully informed of the continuing prosecution and may comment upon such documentation sufficiently in advance of any initial deadline for filing a response, provided, however, that if (a) Licensee has not commented upon such documentation in a
reasonable time to enable The Regents to sufficiently consider Licensee’s comments prior to a deadline with the relevant government patent office, or (b) The Regents must act immediately to preserve the Patent Rights, The Regents will be
free to respond without consideration of Licensee’s comments. All such documentation shall be the Proprietary Information of The Regents, pursuant to Article 31 (Confidentiality). 

 

	 	20.2.	The Regents shall use reasonable efforts to amend any patent application to include claims reasonably requested by Licensee to protect the products contemplated to be
Sold, or the Licensed Methods to be practiced, under this Agreement. 

  

	 	20.3.	 Licensee will apply, in the name of The Regents, for an extension of the term of any patent included within the Patent Rights if appropriate under the
Drug Price Competition and Patent Term Restoration Act of 1984 and/or European, Japanese and other foreign counterparts of this Law. Licensee shall prepare all relevant documents. The Regents

  
 ***
INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED. 
  

					
		 	32	 	***_FivePrime

	 	 
shall cooperate with Licensee in such preparation and shall execute the documents and take additional action as Licensee reasonably requests in connection therewith. Licensee shall be liable for
all costs relating to such application. 

  

	 	20.4.	The Regents shall inform Licensee, in writing, of all Patent Prosecution Costs as soon as practicable and, in the case of patent maintenance fees, at least ***
months prior to their due date. In addition, in the event that any non-routine or unanticipated Patent Prosecution Costs may be incurred (e.g., those relating to an interference proceeding or re-examination), The Regents shall discuss those matters
with Licensee, in advance, and the parties will make diligent efforts to agree upon a strategy and expense parameters with respect thereto. Licensee will bear all Patent Prosecution Costs (to the extent they have not been and are not, in the future,
paid by a third party). Patent Prosecution Costs billed by The Regents’ counsel will be re-billed to Licensee and are due within *** days of Licensee’s receipt of invoice from by The Regents. Patent Prosecution Costs will include,
without limitation, patent prosecution costs for the Invention incurred by The Regents prior to the Effective Date and any costs that may be incurred by The Regents for patentability opinions, re-examination, re-issue, interferences, oppositions or
inventorship determinations with respect to the Invention or the Patent Rights. The parties agree that, of the total amount of Patent Prosecution Costs incurred by The Regents through August 30,2006, the amount payable by Licensee hereunder
shall be $***, less credit for any such costs paid by Licensee prior to the Effective Date. Such amount will be due within *** days of the Effective Date or Licensee’s receipt of invoice therefor from The Regents, whichever is
later, and Licensee’s payment of that amount shall relieve Licensee of any further obligation to pay for Patent Prosecution Costs incurred by The Regents prior to August 30, 2006. 

  
 ***
INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED. 
  

					
		 	33	 	***_FivePrime

	 	20.5.	Licensee may request that The Regents obtain patent protection of the Invention in countries other than those in which the Patent Rights exist, if available and if it
so desires. Licensee will notify The Regents of its decision to obtain such foreign patents not less than *** days prior to the deadline for any payment, filing or action to be taken in connection therewith. The notice shall be in writing,
and shall (a) identify the countries in which such protection is desired, and (b) must confirm Licensee’s obligation to pay the Patent Prosecution Costs thereof The absence of such a notice from Licensee to The Regents will be
considered an election not to obtain or maintain such patent rights. 

  

	 	20.6.	Licensee will be obligated to pay any Patent Prosecution Costs incurred during the *** month period after receipt by either party of a Notice of Termination of
this Agreement, even if the invoices for such Patent Prosecution Costs are received by Licensee after the end of the *** month period following receipt of a Notice of Termination. 

 

	 	20.7.	Licensee may terminate its obligation to pay Patent Prosecution Costs with respect to any given patent application or patent under Patent Rights in any or all
designated countries upon ***-months’ written notice to The Regents. The Regents may continue prosecution and/or maintenance of such application(s) or patent(s) at its sole discretion and expense, provided, however, that Licensee will
have no further right or licenses thereunder. Non-payment of Patent Prosecution Costs when due, followed by Licensee’s failure to make such payment within *** days of receipt of a written notice from The Regents stating that continued
non-payment may result in Licensee’s loss of the relevant Licensed Patents, may be deemed an election by Licensee not to maintain such the application(s) or patent(s) to which such Patent Prosecution costs relate. 

 

	 	20.8.	If The Regents decides to file, prosecute or maintain Patent Rights in any country in which Patent Rights did not exist as of the Effective Date, The Regents shall so
notify Licensee, in writing, and Licensee shall have *** days to elect to pay the reasonable Patent Prosecution Costs thereof Unless Licensee so elects within such ***-day period, The Regents may file, prosecute or maintain such Patent
Rights at its own expense and those Patent Rights will not be subject to this Agreement. 

  
 ***
INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED. 
  

					
		 	34	 	***_FivePrime

	21.	PATENT MARKING 

 Licensee will mark all Licensed
Products it Sells, or their containers, in accordance with the applicable patent marking laws, and shall require all Sublicensees to do the same. 
  

	22.	PATENT INFRINGEMENT 

  

	 	22.1.	If The Regents (to the extent of the actual knowledge of the licensing professional responsible for the administration of this Agreement) or Licensee learns of
infringement of potential commercial significance of any Patent Rights then licensed under this Agreement, the knowledgeable party will promptly provide the other with written notice of such infringement, and any evidence of such infringement
available to it (a “Third-Party Infringement Notice”). As soon as reasonably practicable thereafter, the parties will confer, and during the *** day period following the Third-Party Infringement Notice (the “***-Day
Period”), they will make diligent efforts to cooperate with each other to terminate the infringement without litigation. The parties also will discuss, and tentatively agree on, a course of action to be taken (including the possibility of
bringing a joint action against the infringer) if the infringement does not abate within the ***-Day Period. 

  

	 	22.2.	Unless the parties agree otherwise, in writing, during the ***-Day Period, in any jurisdiction where Licensee has exclusive Patent Rights under this Agreement,
neither The Regents nor Licensee will notify a possible infringer of its infringement of the Patent Rights in any manner that would provide a basis for an action such possible infringer for declaratory judgment, without first obtaining the written
consent of the other party, which shall not be unreasonably withheld. 

  
 ***
INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED. 
  

					
		 	35	 	***_FivePrime

	 	22.3.	If infringing activity with respect to the Patent Rights has not abated within the ***-Day Period: 

22.3.1.     The parties shall join in a suit against the infringer, if they previously have agreed,
in writing, to do so. 
 22.3.2.     If the parties have not agreed to join in a suit,
Licensee shall have the right to initiate suit against the infringer, independently, without the right to join The Regents in the suit, except in the following. If Licensee files a suit independently, and the court in which the suit was filed rules
thereafter the suit cannot proceed without the joinder of The Regents as a party, Licensee will so inform The Regents. Promptly after Licensee has so notified The Regents, The Regents may join the suit voluntarily, or Licensee may bring an action
for compulsory joinder of the Regents in the suit, and Licensee shall bear both parties’ costs of the litigation. Licensee shall not join The Regents in any suit against an infringer hereunder, without The Regents’ prior written consent,
except as expressly provided above. 
 22.3.3.    If Licensee does not file suit pursuant
to Paragraph 22.3.2 within *** days after the effective date of the Third-Party Infringement Notice, or if Licensee informs The Regents, in writing, that it does not intend to file such a suit, The Regents may initiate suit, and Licensee will
not be entitled to join in the suit without The Regents’ written consent. 

22.3.4.    In any litigation instituted by a single party pursuant to this Article 22 (an
“Initiating Party”), unless the parties have agreed otherwise, in writing, (a) the other party shall cooperate with the Initiating Party in the litigation proceedings, at the expense of the Initiating Party, (b) the
Initiating Party shall control the litigation proceedings and (c) a party that joins or is joined in such proceedings after they have been initiated may be represented by counsel of its choice, at its own expense. 

  
 ***
INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED. 
  

					
		 	36	 	***_FivePrime

	 	22.4.	Notwithstanding anything to the contrary in this Agreement, in the event that the infringement or potential infringement pertains to an issued patent included within
the Patent Rights and written notice is received by Licensee or The Regents under the Drug Price Competition and Patent Term Restoration Act of 1984 (and/or foreign counterparts of this Law), then the party in receipt of such notice under the Act
shall promptly provide a copy of the notice to the other party. If the time period is such that Licensee will lose the right to pursue its legal remedies for infringement by not notifying a third party of infringement (including notification in a
manner that could provide a basis for an action by the possible infringer for declaratory judgment), or by not filing suit, the ***-Day Period shall be accelerated to one within *** days of the date of such notice under such Act.

  

	 	22.5.	The costs of litigation incurred in any suit filed pursuant to this Article 22, to the extent it relates to the Patent Rights (as opposed to any other proprietary or
licensed rights of the a party initiating the suit) shall be allocated as follows: 

22.5.1.    In an action brought in accordance with Paragraph 22.3.1, each party shall bear its own
costs. 
 22.5.2.    In an action brought in accordance with Paragraph 22.3.2, Licensee
shall bear all costs. 
 22.5.3.    In an action brought in accordance with Paragraph
22.3.3 by The Regents shall bear all costs, unless Licensee joins in the suit, in which case each party shall bear its own costs. 
  

	 	22.6.	 Any recovery or settlement received in connection with any suit filed pursuant to this Article 22, to the extent it relates to the Patent Rights, will
first be used to reimburse the parties’ costs of litigation and/or assistance therewith. If the award is insufficient to cover all litigation costs, it will be divided between the parties in proportion to the

  
 ***
INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED. 
  

					
		 	37	 	***_FivePrime

	 	 
expenses incurred by each party (e.g., if Licensee bore 60% of the total costs of the litigation, Licensee would receive 60% of the recovery or settlement). Any remainder of the award shall be
allocated as follows: 

 22.6.1.    In an action brought in accordance
with Paragraph 22.3.1, or an action brought in accordance with Paragraph 22.4.3 in which Licensee joins, the remainder shall be divided evenly between the parties. 

22.6.2.    In an action brought in accordance with Paragraph 22.3.2 (and for which Licensee has
borne all costs of litigation), *** percent (***%) of the remainder shall belong to Licensee, and *** percent (***%) shall belong to The Regents. 

22.6.3.    In an action brought in accordance with Paragraph 22.3.3 by The Regents, independently,
*** percent (***%) of the remainder shall belong to The Regents. 
  

	 	22.7.	Any agreement made by Licensee for purposes of settling litigation or other form of dispute with an infringer of the Patent Rights shall comply with the requirements of
Article 4 (Right to Grant Sublicenses), and no agreement made by The Regents for purposes of settling litigation or another dispute with an infringer of the Patent Rights shall be inconsistent with the license granted to Licensee hereunder, unless
the parties agree otherwise, in writing. 

  

	23.	INDEMNIFICATION 

  

	 	23.1.	 Licensee will, and will require its Sublicensees to indemnify, hold harmless and defend The Regents and its officers, employees and agents, the
sponsors of the research that led to the Invention, and the inventors of any invention claimed in patents or patent applications under Patent Rights (including the Licensed Products and Licensed Methods contemplated thereunder) and their employers
against any and all claims, suits, losses, damage, costs, fees and expenses resulting from, or arising out of the exercise of this license or any sublicense. This indemnification will include, but not be limited to, any product liability. If The
Regents, in its sole discretion, believes that there will be a 

  
 ***
INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED. 
  

					
		 	38	 	***_FivePrime

	 	 
conflict of interest or it will not otherwise be adequately represented by counsel chosen by Licensee to defend The Regents in accordance with this Paragraph 23.1, then The Regents may retain
counsel of its choice to represent it and Licensee will pay all expenses for such representation. 

  

	 	23.2.	HHMI and its trustees, officers, employees, and agents (collectively, “HHMI Indemnitees”) employers will be indemnified, defended by counsel acceptable
to HHMI, and held harmless by Licensee from and against any claim, liability, cost, expense, damage, deficiency, loss, or obligation of any kind or nature (including, without limitations, reasonable attorney’s fees and other costs and expenses
of defense) based on, resulting from, arising out of, or otherwise relating to this Agreement or the exercise of this license or any sublicense, including without any limitation cause of action relating to product liability (collectively,
“Claims”). The previous sentence will not apply to any Claim that is determined with finality by a court of competent jurisdiction to result solely from the gross negligence or willful misconduct of an HHMI Indemnitee. For clarity,
acts conducted under the retained rights and licenses set forth in Paragraphs 2.4 and 2.5 are not subject to this indemnification obligation of Licensee or Sublicensees. If HHMI, in its sole discretion, believes that there will be a conflict of
interest or it will not otherwise be adequately represented by counsel chosen by Licensee to defend the HHMI Indemnitees in accordance with this Paragraph 23.2, then HHMI may retain counsel of its choice to represent the HHMI Indemnitees, and
Licensee will pay all expenses for such representation. 

  

	 	23.3.	Licensee, at its sole cost and expense, will insure its activities in connection with any work performed hereunder and will obtain and maintain (or an equivalent
program of self insurance), Comprehensive or Commercial Form General Liability Insurance (contractual liability included) with limits as follows: 

  
 ***
INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED. 
  

					
		 	39	 	***_FivePrime

	 	(a)	From the Effective Date until the date of initiation of the first Phase I Clinical Trial: 

 

					
		 	 •       Each Occurrence
	  	$***
		 	 •       Aggregate
	  	$***
		 	 •       Personal or Advertising Injury
	  	$***

  

	 	(b)	From the date of the initiation of the first Phase I Clinical Trial until the date of the first Sale of a Licensed Product: 

 

					
		 	 •       Each Occurrence
	  	$***
		 	 •       Aggregate
	  	$***
		 	 •       Personal or Advertising Injury
	  	$***

  

	 	(c)	From the date of the first Sale of a Licensed Product through a *** year period following the termination or expiration of this Agreement:

  

					
		 	 •       Each Occurrence
	  	$***
		 	 •       Products/Completed Operations Aggregate
	  	$***
		 	 •       Personal and Advertising Injury 
	  	$***
		 	 •       General Aggregate (Commercial Form only)
	  	$***

  

	 	23.4.	The coverage and limits referred to in Paragraph 23.3 will not in any way limit the liability of Licensee. Licensee will furnish The Regents with certificates of
insurance evidencing compliance with all requirements. Such certificates will: 

  

	 	•	 	 Provide for *** days’ advance written notice to The Regents of any modification; 

	 	•	 	 Indicate that The Regents and HHMI have been endorsed as an additional insured(s) under the coverage described above; and 

	 	•	 	 Include a provision that the coverage will be primary and will not participate with, nor will be excess over, any valid and collectable insurance or
program of self-insurance maintained by The Regents and HHMI. 

  
 ***
INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED. 
  

					
		 	40	 	***_FivePrime

	 	23.5.	The Regents will promptly notify Licensee in writing of any Claim brought against The Regents for which The Regents intends to invoke the provisions of this Article 23.
Licensee will keep The Regents informed of its defense of any claims pursuant to this Article 23. 

  

	 	23.6.	In the case of an HHMI Indemnitee, notice shall be given to Licensee reasonably promptly following actual receipt of written notice thereof by an officer or attorney of
HHMI. Notwithstanding the foregoing, the delay or failure of any HHMI Indemnitee to give prompt notice to Licensee of any Claim shall not affect the rights of such HHMI Indemnitee unless, and then only to the extent that, such delay or failure is
prejudicial to or otherwise adversely affects Licensee. Licensee will keep HHMI informed of its defense of any claims or suits pursuant to this Article 23. 

 

	24.	NOTICES 

  

	 	24.1.	Any notice or payment required to be given to either party under this Agreement will be in writing and will be deemed to have been properly given and to be effective as
of the date specified below, if delivered to the party at its address given below or at another address as designated by written notice given by such party to the other party: 

 

	 	•	 	 On the date of delivery if delivered in person; 

  

	 	•	 	 On the date of mailing if mailed by first-class certified mail, postage prepaid; 

 

	 	•	 	 On the date of mailing if mailed by any global express carrier service that requires the recipient to sign the documents demonstrating the delivery of
such notice or payment; or 

  

	 	•	 	 On the date of transmission via facsimile (with receipt confirmed by automatic transmission report). 

 

			
	 In the case of Licensee:
	 	 Copy to:

		
	Five Prime Therapeutics Inc.	 	Five Prime Therapeutics Inc.
	1650 Owens Street Suite 200	 	1650 Owens Street, Suite 200
	San Francisco, California, 94158	 	San Francisco, California, 94158

  
 ***
INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED. 
  

					
		 	41	 	***_FivePrime

			
	Attn: President & CEO	 	Attn: V.P. of Intellectual Property
	Facsimile (415) 365-5601	 	Facsimile (415) 365-5601
		
	In the case of The Regents:	 	
		
	For notices:	 	Office of Technology Management
		 	 University of California, San Francisco
 185 Berry Street, Suite 4603
 San Francisco, CA 94107

Attention: Director
 Facsimile:
(415) 348-1579
 RE: UC Case No. ***

		
	For remittance
    of payments	 	 Office of Technology Transfer

Attn: Accounts Receivable (Case No. ***)
 University of California
 Office of the President

1111 Franklin Street,
7th Floor

Oakland, CA 94607-5200

  

	25.	ASSIGNABILITY 

 This Agreement is personal to
Licensee. Licensee may not assign or transfer this Agreement, including by merger, operation of law, or otherwise, without The Regents’ prior written consent, which consent shall not be unreasonably withheld, except that such consent will not
be required in the case of assignment or transfer to a party that succeeds to all or substantially all of Licensee’s business or assets relating to this Agreement, whether by sale, merger, operation of law or otherwise, provided that such
assignee or transferee promptly agrees to be bound by the terms and conditions of this Agreement and signs The Regents’ standard substitution of party letter (the form of which is attached hereto as Appendix B). Any attempted assignment by
Licensee in violation of this Article 25 will be null and void. This Agreement shall be binding upon and shall inure to the benefit of The Regents, its successors and assigns and Licensee, its successors and its permitted assigns. 

  
 ***
INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED. 
  

					
		 	42	 	***_FivePrime

	26.	WAIVER 

 No waiver by either party of any breach
or default of any of the covenants or agreements contained herein will be deemed a waiver as to any subsequent and/or similar breach or default. No waiver will be valid or binding upon the parties unless made in writing and signed by a duly
authorized officer of each party. 
  

	27.	FORCE MAJEURE 

  

	 	27.1.	Except for Licensee’s obligation to make any payments to The Regents hereunder, the parties shall not be responsible for any failure to perform their respective
obligations hereunder due to the occurrence of any events beyond their reasonable control which render their performance impossible or onerous, including, but not limited to accidents (environmental, toxic spills, etc.); acts of God; biological or
nuclear incidents; casualties; earthquakes; fires; floods; governmental acts; orders or restrictions; inability to obtain suitable and sufficient labor, transportation, fuel and materials; local, national or state emergency; power failure or power
outages; acts of terrorism; strike; and war. 

  

	 	27.2.	Either party to this Agreement, however, will have the right to terminate this Agreement upon *** days’ prior written notice if either party is unable to
fulfill its obligations under this Agreement due to any of the causes specified in Paragraph 27.1 for a period of *** year. 

  

	28.	GOVERNING LAWS; VENUE; ATTORNEYS’ FEES 

  

	 	28.1.	This Agreement will be interpreted and construed in accordance with the laws of the State of California, excluding any choice of law rules that would direct the
application of the laws of another jurisdiction and without regard to which party drafted particular provisions of this Agreement, but the scope and validity of any patent or patent application within the Patent Rights will be governed by the
applicable laws of the country of such patent or patent application. 

  
 ***
INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED. 
  

					
		 	43	 	***_FivePrime

	 	28.2.	Any legal action brought by the parties hereto relating to this Agreement will be conducted in San Francisco, California. 

 

	 	28.3.	The prevailing party in any suit related to this Agreement will be entitled to recover its reasonable attorneys’ fees, in addition to its costs and necessary
disbursements. 

  

	29.	GOVERNMENT APPROVAL OR REGISTRATION 

 If this
Agreement or any associated transaction is required by the law of any nation to be either approved or registered with any governmental agency, Licensee will assume all legal obligations to do so. Licensee will notify The Regents if it becomes aware
that this Agreement is subject to a United States or foreign government reporting or approval requirement. Licensee will make all necessary filings and pay all costs including fees, penalties and all other out-of-pocket costs associated with such
reporting or approval process. 
  

	30.	COMPLIANCE WITH LAWS 

 Licensee shall comply with
all applicable international, national, state, regional and local laws and regulations in pertaining its obligations hereunder and in its use, manufacture, Sale or import of the Licensed Products, or practice of the Licensed Method. Licensee will
observe all applicable United States and foreign laws with respect to the transfer of Licensed Products and related technical data to foreign countries, including, without limitation, the International Traffic in Arms Regulations (ITAR) and the
Export Administration Regulations. Licensee shall manufacture Licensed Products and practice the Licensed Method in compliance with applicable government importation laws and regulations of a particular country for Licensed Products made outside the
particular country in which such Licensed Products are used or Sold. 

  
 ***
INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED. 
  

					
		 	44	 	***_FivePrime

	31.	CONFIDENTIALITY 

  

	 	31.1.	Licensee and The Regents will treat and maintain the other party’s proprietary business, patent prosecution, software, engineering drawings, process and technical
information and other proprietary information, including the negotiated twits of this Agreement and any progress reports and Quarterly Reports (“Proprietary Information”) in confidence using at least the same degree of care as the
receiving party uses to protect its own proprietary information of a like nature from the date of disclosure until *** years after the termination or expiration of this Agreement. 

 

	 	31.2.	Licensee and The Regents may use and disclose Proprietary Information to their employees, agents, consultants, contractors and, in the case of Licensee, Joint Ventures,
Sublicensees, potential Sublicensees, any potential or actual parties collaborating with Licensee in the research, development, manufacture or marketing of a Licensed Product, and any potential or actual investors in Licensee, provided that such
parties are bound by a like duty of confidentiality as that found in this Article 31 (Confidentiality). 

  

	 	    	Notwithstanding anything to the contrary contained in this Agreement, The Regents may release this Agreement, including any terms contained herein and information
regarding Royalties or other income received by The Regents in connection with this Agreement to the inventors, senior administrative officials employed by The Regents and individual Regents and to the senior administrative officials employed by
HHMI and individual trustees of HHMI upon their request, provided that each recipient is bound to obligations of confidentiality at least as strict as those contained in this Article 31. In addition, notwithstanding anything to the contrary in this
Agreement, if a third party inquires whether a license to Patent Rights is available, then The Regents may disclose the existence of this Agreement and the extent of the grant in Articles 2 (Grant) and 4 (Right to Grant Sublicenses) and related
definitions to such third party, but will not disclose the name of Licensee or other terms of this Agreement unless Licensee has already made such disclosure publicly. 

  
 ***
INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED. 
  

					
		 	45	 	***_FivePrime

	 	31.3.	All written Proprietary Information will be labeled or marked confidential or proprietary. If the Proprietary Information is orally disclosed, it will be reduced to
writing or some other physically tangible form, marked and labeled as confidential or proprietary by the disclosing party and delivered to the receiving party within *** days after the oral disclosure. 

 

	 	31.4.	Nothing contained herein will in any way restrict or impair the right of Licensee or The Regents to use or disclose any Proprietary Information:

 31.4.1. That recipient can demonstrate by written records was previously known to it prior to
its receipt from the disclosing party; 
 31.4.2. That is now, or becomes in the future, public knowledge other
than through acts or omissions of recipient; 
 31.4.3. That recipient can demonstrate by written records was
lawfully obtained from sources independent of the disclosing party; or 
 31.4.4. That The Regents is required
to disclose pursuant to the California Public Records Act or other applicable law. 
  

	 	31.5.	Licensee or The Regents also may use or disclose Proprietary Information that is required to be disclosed (a) to a governmental entity or agency in connection with
seeking any governmental or regulatory approval, governmental audit, or other governmental contractual requirement or (b) by law, provided that the recipient uses reasonable efforts to give the party owning the Proprietary Information
sufficient notice of such required disclosure to allow the party owning the Proprietary Information reasonable opportunity to object to, and to take legal action to prevent, such disclosure. 

 

	 	31.6.	Upon termination of this Agreement, Licensee and The Regents will destroy or return any of the disclosing party’s Proprietary Information in its possession, within
*** days following the termination of this Agreement. Licensee and The Regents will provide each other, within *** days following termination, with written certification that such Proprietary Information has been returned or destroyed.
Each party may, however, retain one copy of such Proprietary Information for archival purposes in its legal files, for purposes of monitoring compliance with this Article 31. 

  
 ***
INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED. 
  

					
		 	46	 	***_FivePrime

	32.	MISCELLANEOUS 

  

	 	32.1.	The headings of the several sections are inserted for convenience of reference only and are not intended to be a part of or to affect the meaning or interpretation of
this Agreement. 

  

	 	32.2.	This Agreement is not binding on the parties until it has been signed below on behalf of each party. It is then effective as of the Effective Date.

  

	 	32.3.	No amendment or modification of this Agreement is valid or binding on the parties unless made in writing and signed on behalf of each party. 

 

	 	32.4.	This Agreement embodies the entire understanding of the parties and supersedes all previous communications, representations or understandings, either oral or written,
between the parties relating to the subject matter hereof. The Letter of Intent (UC Control No. ***) dated March 7, 2006 is hereby terminated. 

  

	 	32.5.	In case any of the provisions contained in this Agreement is held to be invalid, illegal or unenforceable in any respect, such invalidity, illegality or
unenforceability will not affect any other provisions of this Agreement and this Agreement will be construed as if such invalid, illegal or unenforceable provisions had never been contained in it. 

 

	 	32.6.	No provisions of this Agreement are intended or shall be construed to confer upon or give to any person or entity other than The Regents and Licensee any rights,
remedies or other benefits under, or by reason of, this Agreement. 

  

	 	32.7.	In performing their respective duties under this Agreement, each of the parties will be operating as an independent contractor. Nothing contained herein will in any way
constitute any association, partnership, or joint venture between the parties, or be construed to evidence the intention of the parties to establish any such relationship. Neither party will have the power to bind the other party or incur
obligations on the other party’s behalf without the other party’s prior written consent. 

  
 ***
INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED. 
  

					
		 	47	 	***_FivePrime

	 	32.8.	HHMI is not a party to this Agreement and has no liability to Licensee, Sublicensees, or users of anything covered by this Agreement, but HHMI is an intended
third-party beneficiary of this Agreement, and certain of its provisions are for the benefit of HHMI and are enforceable by HHMI in its own name. 

 IN WITNESS WHEREOF, both The Regents and Licensee have executed this Agreement, in duplicate originals, by their respective and duly authorized officers on the day and year written. 

 

									
	FIVE PRIME THERAPEUTICS, INC.:	 		 	THE REGENTS OF THE UNIVERSITY OF CALIFORNIA:
					
	By:	 	    /s/ Gail J.
Maderis                    	 		 	By:	 	    /s/ Joel B. Kirschbaum            
		 	Gail J. Maderis	 		 		 	Joel B. Kirschbaum, Ph.D.
		 	President & CEO	 		 		 	 Director, UCSF Office of

    Technology Management

					
	Date:  	 	      September 11, 2006            	 		 	Date:  	 	    9/12/06                    

  
 ***
INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED. 
  

					
		 	48	 	***_FivePrime

 APPENDIX A 
 Part 1: UC Patent Rights 
 *** 

  
 ***
INDICATES ONE PAGE OF MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT
OF 1933, AS AMENDED. 
  

					
		 	A-1	 	***_FivePrime

 APPENDIX B 
 EXCLUSIVE LICENSE 
 FOR 

RECEPTORS FOR FIBROBLAST GROWTH FACTORS 
 UC Case No. *** 
 CONSENT TO SUBSTITUTION OF PARTY 

This substitution of parties (“Agreement”) is effective this
             day of             ,             ,
among the Regents of the University of California (“The Regents”), a California corporation, having its statewide administrative offices at 1111 Franklin Street, 12th Floor, Oakland, California 94607-5200 and acting through its Office of
Technology Management, University of California San Francisco, 185 Berry Street, Suite 4603, San Francisco, CA 94107; FivePrime Therapeutics Inc. (“FivePrime”), a Delaware corporation, having a principal place of business at 1650
Owens Street, Suite 200, San Francisco, CA 94158 and [new licensee name] [(“YYY”)] a
                                         
    corporation, having a principal place of business at
                                         
                   . 

BACKGROUND 
 A.
The Regents and FivePrime entered into an Exclusive License Agreement for UC Case No. *** effective ***, 2006, UC Control No.             , entitled “Receptors for
Fibroblast Growth Factors” (“License Agreement”), wherein FivePrime was granted certain rights. 
 B. FivePrime
desires that [YYY] be substituted as [Licensee] (defined in the License Agreement) in place of [XXX], and The Regents is agreeable to such substitution. 
 C. [YYY] has read the License Agreement and agrees to abide by its terms and conditions. 

  
 ***
INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED. 
  

					
		 	B-1	 	***_FivePrime

 The parties agree as follows: 

A. [YYY] assumes all liability and obligations under the License Agreement and is bound by all its terms in all respects as if it were the
original Licenses of the License Agreement in place of FivePrime. 
 B. [YYY] is substituted for FivePrime, provided that [YYY]
assumes all liability and obligations under the License Agreement as if [YYY] were the original party named as Licensee as of the effective date of the License Agreement. 
 C. The Regents releases FivePrime from all liability and obligations under the License Agreement arising before or after the effective date of this Agreement. 

The parties have executed this Agreement in triplicate originals by their respective authorized offices on the following day and year.

  

									
	FIVE PRIME THERAPEUTICS, INC.	 		 	 THE REGENTS OF THE
  

UNIVERSITY OF CALIFORNIA

					
	By:	 	 	 		 	By:	 	 
					
		 	            (Signature)	 		 		 	            (Signature)
					
	Name:	 	 	 		 	Name:	 	 
					
		 	            (Please print)	 		 		 	            (Please print)
					
	Title:	 	 	 		 	Title:	 	 
					
	Date:	 	 	 		 	Date:	 	 
				
	[YYY] COMPANY	 		 		 	
					
	By:	 	 	 		 		 	
					
		 	            (Signature)	 		 		 	
					
	Name:	 	 	 		 		 	
				
	(Please print)	 		 		 	
					
	Title:	 	 	 		 		 	
					
	Date:	 	 	 		 		 	

  
 ***
INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED. 
  

					
		 	B-2	 	***_FivePrime

 APPENDIX C 

  
 ***
INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED. 
  

					
		 	C-1	 	***_FivePrime

 LICENSE AGREEMENT 

THIS LICENSE AGREEMENT is made and entered into as of July 18, 2006 (the “Effective Date”), by and
between The Regents of the University of California as represented by the University of California, San Francisco through its Office of Technology Management having its principal place of business at 185 Berry Street, Suite 4603, San Francisco,
California 94107 (“UCSF”), and Novartis Vaccines and Diagnostics, Inc. (formerly Chiron Corporation), a Delaware corporation having its principal place of business at 4560 Horton Street, Emeryville, California 94608
(“Novartis V&D”). 
 BACKGROUND 

WHEREAS, On April 20, 2006, Chiron Corporation became part of the Novartis group of companies under the name Novartis
Vaccines and Diagnostics, Inc. pursuant to a reverse triangular merger. Novartis V&D is a wholly-owned indirect subsidiary of Novartis A.G. 
 WHEREAS, Novartis V&D is the owner of certain patents covering fibroblast growth factor receptor as further defined below; 

WHEREAS, UCSF desires to obtain an exclusive license under such patents; and 

WHEREAS, Novartis V&D is willing to grant such a license to UCSF under the terms and conditions set forth herein. 

NOW, THEREFORE, in consideration of the above premises and the mutual covenants contained herein, the parties hereto agree as
follows: 
  

	1.	DEFINITIONS 

 For
the purposes of this Agreement, the following definitions shall apply, and the terms defined herein in plural shall include the singular and vice-versa: 
 1.1. “Fees” means any and all fees, payments or other consideration (including upfront fees, milestone fees, royalty fees and other compensation). 

1.2. “License Fee” has the meaning set forth in Section 3.1. 

1.3. “Licensed Patents” means U.S. Patent No. 6,656,728 entitled “Fibroblast Growth Factor
Receptor-Immunoglobulin Fusion,” and its foreign counterparts. 
 1.4. “Licensed Products” means
applications of the Licensed Patents, the manufacture, use or sale of which would, but for this license, infringe one or more claims of a Licensed Patent. 

  
 ***
INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED. 
  

					
	 Final
	 		 	Page 1 of 6

	2.	LICENSE GRANT BY NOVARTIS V&D  

 Subject to the terms hereof, Novartis V&D hereby grants to UCSF a worldwide, exclusive license (with the right to grant sublicenses) under the Licensed Patents to make, have made, use, sell, offer for
sale and import Licensed Products. 
  

	3.	PAYMENTS TO NOVARTIS V&D 

 3.1. License Fee. UCSF shall pay Novartis V&D *** percent (***%) of any Fees that UCSF receives from any exploitation of the Licensed Patents or any commercialization of the
Licensed Products, including without limitation any Fees that UCSF receives from any sublicense (the “License Fee”). For the avoidance of doubt, the License Fee shall not be prorated for the estimated value of the Licensed Patents if the
scope of any Licensed Product or the scope of any sublicense is broader than the rights under the Licensed Patents. UCSF shall make payment of the License Fee to Novartis V&D on a quarterly basis, as of the last day of March, June, September and
December, respectively, for the calendar quarter ending on that date. For any calendar quarter in which any License Fee is payable to Novartis V&D, UCSF shall also submit to Novartis V&D, along with the License Fee, a quarterly report
setting out Fees that UCSF received and the source(s) for each of such Fees, and if such Fees were derived from a Licensed Product, the Fees received from each Licensed Product by product and country. 

3.2. Manner of Payment. All payments hereunder shall be in United States dollars in immediately available funds and shall be made
by wire transfer to such bank account as may be designated from time to time by Novartis V&D. UCSF shall also comply with all payment instructions provided by Novartis V&D and complete all payment forms required by Novartis V&D.

 3.5. Taxes. Where required to do so by applicable law or treaty, UCSF shall or cause its sublicensees to withhold
taxes required to be paid to a taxing authority on account of such income to Novartis V&D, and UCSF shall furnish Novartis V&D with satisfactory evidence of such withholding and payment in order to permit Novartis V&D to obtain a tax
credit or other relief as is available under the applicable law or treaty. 
  

	4.	RECORDS AND REPORTS 

 4.1. Records of Payment Obligations. UCSF will keep and maintain proper books and records as are required accurately to determine License Fees payable to Novartis V&D for *** years
following the date on which such License Fees were paid or reported. Novartis V&D or its accountant shall have the right, at its own expense, to examine such books and records at reasonable times solely for the purpose of verifying the accuracy
of License Fees paid or reported by UCSF. If such examination reveals an underpayment, then UCSF shall promptly make up such underpayment with interest, and, if the underpayment exceeds ***%, UCSF shall bear the cost of the examination.

  
 ***
INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED. 
  

					
	 Final
	 		 	Page 2 of 6

 4.2. Reports. Within *** days after the close of each fiscal year, UCSF shall
provide Novartis V&D with a written report setting forth in reasonable detail the results of its development work with respect to the Licensed Products. 
  

	5.	PATENTS 

 5.1.
Infringement. UCSF, at its expense, shall be responsible for prosecuting, maintaining and defending the Licensed Patents, and Novartis V&D, at UCSFs expense, shall reasonably cooperate in any such matter. If a third party sues UCSF for
alleged infringement of a third party patent by reason of sale of Licensed Products, UCSF shall have the sole responsibility, at its own expense, to defend all such suits directly or through defense and indemnification by a sublicensee. Novartis
V&D shall have no liability with respect to any such third-party patents and UCSF hereby indemnifies Novartis V&D from any costs, expenses, damages, claims or losses, with respect to any claims or causes of action based on such third-party
patents which indemnification may be satisfied by indemnification by a sublicensee. 
 5.2. Patent Matters. In
consideration of the licenses granted herein, UCSF shall refrain from any participation in or initiation of any opposition, interference or conflict involving the Licensed Patents. 

5.3 Patent Abandonment. UCSF shall not abandon or permit to lapse any Licensed Patent without prior the written consent of
Novartis V&D. Should UCSF determine that it no-longer wishes to. maintain any Licensed Patent, UCSF shall notify Novartis V&D in writing promptly, but in no event less than *** days prior to the date on which any required maintenance
fee or responsive filing is due (without any extension of time) to the relevant authority for the affected Licensed Patent. In no event shall such notification occur later than the date on which such Licensed Patent is deemed abandoned. Should
Novartis V&D wish to resume prosecution, maintenance or defense of such Licensed Patent following notification by UCSF of its intent to abandon the Licensed Patent, UCSF agrees to cooperate with Novartis V&D to enable Novartis V&D to
resume prosecution, maintenance and defense of any such Licensed Patent, including without limitation providing documents filed with, or correspondence sent to or received from, the U.S. Patent and Trademark Office or any other relevant authority.
The license granted pursuant to Section 2 with respect to any such Licensed Patent shall immediately terminate upon UCSF’s giving of any such notice of its intent to abandon or permit to lapse any such Licensed Patent. 

 

	6.	TERM AND TERMINATION 

 6.1. Term. Unless earlier terminated in accordance with this Section 6, this Agreement and the licenses granted hereunder shall expire on the later of (i) the expiration date of the last
to expire of the Licensed Patents, or (ii) the receipt of final payment obligation from all sublicensees. 

  
 ***
INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED. 
  

					
	 Final
	 		 	Page 3 of 6

 6.2. Termination. UCSF may terminate this Agreement at any time upon *** days
prior written notice to Novartis V&D. Novartis V&D may terminate this Agreement (including all licenses which may be granted hereunder) by written notice to UCSF if UCSF materially breaches a material provision of this Agreement and has
failed to cure or demonstrate the nonexistence of the breach within *** days of receipt of a written notice and demand to cure such breach. 
 6.3. Effect of Termination. Upon termination of this Agreement, UCSF shall cease all sales of Licensed Products and shall render an accounting to Novartis V&D of any License Fee which may be
due, and the sublicenses granted hereunder shall expire. Notwithstanding anything to the contrary, the termination or expiration of this Agreement shall not excuse UCSF from the payment of License Fees in accordance with the payment provisions of
Section 3. 
  

	7.	NOTICES 

 Any
notice required or permitted to be given by this Agreement shall be given by postpaid, first class, registered or certified mail addressed as set forth below unless changed by notice so given: 

 

			
	 For Novartis V&D:
	  	For UCSF:
	  
 Novartis Vaccines and Diagnostics,
Inc.
 4560 Horton Street
 Emeryville, California 94608
  
 Attention: General Counsel 
	  	  
 Office of Technology Management

University of California, San Francisco
 185
Berry Street, Suite 4603
 San Francisco, CA 94107
 Attention: Director

	 Royalty reports to: Novartis V&D Accounts 
	  	        RE: UC Case No. ***
	    Receivable
	  	

  

	8.	FORCE MAJEURE 

Neither party to this Agreement shall be liable for delay or failure in the performance of any of its obligations hereunder if such delay
or failure is due to causes beyond its reasonable control, including, without limitation, acts of God, fires, earthquakes, strikes and labor disputes, acts of war, civil unrest, or intervention of any governmental authority, but any such delay or
failure shall be remedied by such party as soon as is reasonably possible. 
  

	9.	USE OF NAMES 

Neither party shall use the name of the other in any promotional materials or advertising without the prior written consent of the other.

  
 ***
INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED. 
  

					
	 Final
	 		 	Page 4 of 6

	10	ASSIGNMENT 

 UCSF
shall have no right to assign this Agreement without the prior written consent of Novartis V&D. Novartis V&D may assign its rights and obligations hereunder upon reasonable notice to UCSF. Subject to the foregoing, this Agreement shall inure
to the benefit of and be binding on the parties’ permitted assigns, successors in interest and subsidiaries. 
  

	11.	WAIVERS AND MODIFICATIONS 

 The failure of any party to insist on the performance of any obligation hereunder shall not act as a waiver of such obligation. No waiver, modification, release or amendment of any obligation under this
Agreement shall be valid or effective unless in writing and signed by both parties hereto. 
  

	12.	NO WARRANTY 

 The
licenses granted hereunder by NOVARTIS V&D are provided WITHOUT WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR ANY OTHER WARRANTY, EXPRESS OR IMPLIED. NOVARTIS V&D MAKES NO WARRANTY THAT UCSF’S ACTIVITIES UNDER SAID
LICENSES WILL NOT INFRINGE ANY PATENT OR OTHER PROPRIETARY RIGHT OF A THIRD PARTY. Novartis V&D will not be liable for such infringement, or allegation thereof, nor shall same be an excuse for nonperformance of UCSF’s obligations hereunder.
FURTHER, NOVARTIS V&D MAKES NO REPRESENTATIONS OR WARRANTIES OF ANY KIND, INCLUDING WITHOUT LIMITATION, WITH RESPECT TO THE VALIDITY OR ENFORCEABILITY OF ANY LICENSED PATENT OR THE NON-INFRINGEMENT OF ANY LICENSED PRODUCT. 

 

	13.	PRODUCT INDEMNITY 

UCSF shall indemnify, defend and hold harmless Novartis V&D and its affiliates and their officers and directors for any claim,
demand, or injury arising out of any actions of UCSF, or the manufacture, use or sale by UCSF of any Licensed Product which may be satisfied by an indemnity clause in sublicense agreement. 

 

	14.	UCSF COVENANTS  

UCSF agrees that all of its activities related to its use of the Licensed Patents pursuant to this Agreement shall comply in all material
respects with all applicable legal and regulatory requirements. UCSF further agrees that it shall not engage in any activities that would infringe the Licensed Patents and are outside the scope of the License granted hereunder. 

  
 ***
INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED. 
  

					
	 Final
	 		 	Page 5 of 6

	15.	CHOICE OF LAW 

This Agreement shall be governed by and shall be construed in accordance with the laws of the State of California without regard to the
conflicts of laws provisions thereof. 
  

	16.	PROVISIONS CONTRARY TO LAW 

 In performing this Agreement, the parties shall comply with all applicable laws. Wherever there is any conflict between any provision of this Agreement and any law, the law shall prevail, but in such
event the affected provision of this Agreement shall be limited or eliminated only to the extent necessary, and the remainder of this Agreement shall remain in full force and effect. In the event the terms of this Agreement are materially altered as
a result of the foregoing, the parties shall renegotiate in good faith the terms of this Agreement to resolve any inequities. 
  

	18.	ENTIRE AGREEMENT 

This Agreement constitutes the entire agreement between the parties as to the subject matter hereof, and all prior negotiations,
representations, agreements and understandings are merged into, extinguished by and completely expressed by this Agreement. 
 IN WITNESS
WHEREOF, the parties have duly executed this Agreement on the date(s) written below. 
  

									
	 NOVARTIS VACCINES AND

 
 DIAGNOSTICS, INC.
	 		 	 UNIVERSITY OF CALIFORNIA, SAN

 
 FRANCISCO

					
	By	 	/s/ Jaime Escobedo	 		 	By	 	/s/ Joel B. Kirschbaum
		 	Signature	 		 		 	Signature
			
	Name: Jaime Escobedo	 		 	Name: Joel B. Kirschbaum, Ph.D.
	Title: Vice President, Research	 		 	Title: Director
		 		 	UCSF Office of Technology Management
					
	Date:	 	 7/14/06
	 		 	Date:	 	 8/2/06

  
 ***
INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED. 
  

					
	 Final
	 		 	Page 6 of 6EX-10.30

 Exhibit 10.30 
 *** INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 
  

			
	CONFIDENTIAL	  	Execution Copy

 NON-EXCLUSIVE LICENSE AGREEMENT 

THIS NON-EXCLUSIVE LICENSE AGREEMENT (this “Agreement”), effective as of February 6, 2012 (the
“Effective Date”), is entered into by and among BioWa, Inc., a Delaware corporation, with a principal place of business at 212 Carnegie Center, Suite 101, Princeton, New Jersey 08540, USA (“BioWa”); Lonza
Sales AG, a Swiss corporation, with a principal place of business at Munchensteinerstrasse 38, Basel, CH-4002 Switzerland (“Lonza” and, together with BioWa, the “Licensor”); and Five Prime Therapeutics,
Inc., a Delaware corporation, with a place of business at Two Corporate Drive, South San Francisco, California 94080, USA (“Licensee”). Lonza, BioWa, Licensor or Licensee may hereafter be referred to individually as a
“Party” and collectively as the “Parties.” 
 BACKGROUND 

WHEREAS, Lonza and BioWa have combined Lonza’s GS System and BioWa’s Potelligent® Technology and their related intellectual property to jointly create Potelligent® CHOK1SV for use in combination with the Vectors (all as herein defined); and 

WHEREAS, Licensee wishes to acquire certain nonexclusive rights to the Licensed Technology (as herein defined) to research and
develop monoclonal antibodies capable of specifically binding to the Commercial Target; and 
 WHEREAS, Licensor is
willing to grant such license to the Licensed Technology and Licensee desires to take such license, subject to the terms and conditions in this Agreement. 
 NOW, THEREFORE, in consideration of the mutual covenants and agreements contained herein, the Parties, intending to be legally bound, agree as follows: 

ARTICLE 1—DEFINITIONS 
 Words or phrases having their initial letter capitalized shall, except as clearly provided otherwise in this Agreement or in the context in which they are used, have the respective meanings set forth
below. A cross-reference below to a defined term in this Agreement is for the convenience of the reader of this document, and this Article 1 may not contain an exhaustive list of all words or phrases defined elsewhere in this Agreement. 

1.1 “Activities” means the research, development, manufacturing and commercialization activities conducted using the Licensed
Technology performed by Licensee and any permitted Sublicensee under this Agreement. 
 1.2 “ADCC” means
antibody-dependent cell-mediated cytotoxicity. 

			
	CONFIDENTIAL	  	Execution Copy

  

 1.3 “Affiliate” means any corporation, company, partnership, joint venture, firm
or other business entity which controls, is controlled by, or is under common control with a Party. For purposes of this definition, “control” shall be presumed to exist if one of the following conditions is met: (a) in the case of
corporate entities, direct or indirect ownership of at least fifty percent (50%) of the stock or shares having the right to vote for the election of directors, and (b) in the case of non-corporate entities, direct or indirect ownership of
at least fifty percent (50%) of the equity interest with the power to direct the management and policies of such non-corporate entities. The Parties acknowledge that in the case of certain entities organized under the laws of certain countries,
the maximum percentage ownership permitted by law for a foreign investor may be less than fifty percent (50%), and that in such case such lower percentage shall be substituted in the preceding sentence, provided that such foreign investor has
the power to direct the management and policies of such entities. 
 1.4 “Antibody” means any monoclonal antibody,
antibody fragment or peptide derived therefrom, made through use of the Licensed Technology. For purposes of this Agreement, “derived” shall mean obtained, developed, created, synthesized, designed, resulting from or otherwise generated
(whether directly or indirectly, or in whole or in part). For purpose of clarity, Antibody shall include any monoclonal antibody, any CDR (complementarity determining region), variable or constant region, any single chain antibody, any partially or
fully humanized antibody, any peptides identified through antibody phage display, and any peptide derived from one or more antibodies based on the sequence and structure information of the antibodies, e.g. binding site information of the antibodies,
provided that such Antibody was made through use of the Licensed Technology. 
 1.5 “Approval” means, with
respect to a Product in a particular jurisdiction, the technical, medical and scientific licenses, registrations, authorizations and approvals (including approval of a BLA, and pricing and Third Party reimbursement approvals, and labeling approvals
with respect thereto) of any national, supra-national, regional, state or local regulatory agency or other governmental authority, necessary for the commercial manufacture, distribution, marketing, promotion, offer for sale, use, import, export and
sale of a Product. 
 1.6 “Bankruptcy Code” means Title 11 of the United States Code. 

1.7 “Biologics License Application” or “BLA” means a Biologics License Application and amendments thereto filed
pursuant to the requirements of the FDA, as defined in 21 CFR §600 et seq., for FDA approval of a Product and “sBLA” means a supplemental BLA, and any equivalent or a New Drug Application, as defined in the U.S. Federal Food,
Drug and Cosmetic Act, as amended, and the regulations promulgated thereunder, and any corresponding non-U.S. marketing authorization application, registration or certification, necessary to market a Product in any country outside the U.S., but not
including applications for pricing and reimbursement approvals. 
 1.8 “BioWa Commercial License Fee” has the meaning
set forth in Section 6.2. 
 1.9 “BioWa Royalties” has the meaning set forth in Section 6.5.1. 

  
 *** INDICATES MATERIAL
THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.

  
 2 

			
	CONFIDENTIAL	  	Execution Copy

  

 1.10 “Blank Rome LLP” means the law firm of Blank Rome LLP,
a limited liability partnership having a principal place of business at One Logan Square, 130 North 18th Street, Philadelphia, Pennsylvania 19103, USA. 
 1.11 “Business Day”
means any day that is not a Saturday, Sunday or other day on which commercial banks in New York, New York, United States are required or authorized by law to be closed. 
 1.12 “Calendar Quarter” means each three-month period commencing on January 1, April 1, July 1 or October 1 of each year during the Term. 

1.13 “Calendar Year” means a period of twelve (12) consecutive months ending on December 31. 

1.14 “CFR” means the Code of Federal Regulations of the United States. 
 1.15 “CHOK1SV Cell Line” means Lonza’s suspension variant host Chinese Hamster Ovary (CHO) cell line. 
 1.16 “Commencement” means, with respect to a Phase I, Phase II or Phase III Clinical Trial, the date upon which the first human subject in such clinical trial is administered the
first dose. 
 1.17 “Commercial License” has the meaning set forth in Section 2.1. 

1.18 “Commercial Target” means the Target for which Licensee is granted a Commercial License hereunder. 

1.19 “Competing Contract Manufacturer” means any Third Party that, together with such Third Party’s Affiliates, received
revenue from Third Party’s that are not Affiliates of such Third Party in its prior fiscal year from the manufacture of monoclonal antibodies or therapeutic proteins or any product of a similar nature to which this Agreement relates, which
revenue comprised more than fifty percent (50%) of the total amount of consolidated revenue recorded by such Third Party and such Third Party’s Affiliates. 
 1.20 “Confidential Information” means all confidential or other proprietary information of a Party, whether written, oral or otherwise, including confidential or proprietary
Know-How or other information, whether or not patentable, regarding a Party’s technology, products, business information or objectives, in each case that is clearly designated or marked as confidential, or which under the circumstances
surrounding disclosure or given the nature of the information would reasonably be believed to be confidential. Confidential Information shall not be deemed to include information that the receiving Party can demonstrate by written documentation:
(i) is now, or hereafter becomes, through no act or failure to act on the part of the receiving Party, in the public domain or generally publicly available; (ii) is rightfully known by the receiving Party or its

  
 *** INDICATES MATERIAL
THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.

  
 3 

			
	CONFIDENTIAL	  	Execution Copy

  

 
Affiliates without restriction on disclosure at the time of receiving such information, as evidenced by credible evidence; (iii) is furnished to the receiving Party or its Affiliates by a
Third Party under no obligation of confidentiality, as a matter of right and without restriction on disclosure; or (iv) is independently discovered or developed by the receiving Party or its Affiliates without reference to or use of the
disclosing Party’s Confidential Information. 
 1.21 “Control” or “Controlled” means, with respect
to any Know-How, Patent or Confidential Information, that a Party has the legal authority or right (whether by ownership, license or otherwise) to grant a license or a sublicense to use or disclose such Know-How, Patent or Confidential Information
without violating or breaching the terms of any agreement, covenant, arrangement or undertaking with or obligation to a Third Party, or misappropriating the proprietary or trade secret information of a Third Party. 

1.22 “FDA” means the U.S. Food and Drug Administration and any successors thereto and its non-U.S. counterparts throughout the
world. 
 1.23 “Field” means the diagnosis, prevention, palliation, treatment or cure of human diseases or conditions.

 1.24 “First Commercial Sale” means, with respect to any Product in any country, the first bona fide commercial
sale by Licensee or its Sublicensee to a Third Party (other than a Sublicensee) of such Product following an Approval in such country. 

1.25 “GS System” means Lonza’s glutamine synthetase gene expression system consisting of the CHOK1SV Cell Line, the
Transfection Supplements System, the Vectors, and the related Know-How and Patents, whether used individually or in combination with each other. 
 1.26 “IND” means an Investigational New Drug application, as defined in the U.S. Federal Food, Drug and Cosmetic Act, as amended, and the regulations promulgated thereunder, or any
corresponding non-U.S. application, registration or certification necessary to transport or distribute investigational new drugs for clinical testing in any country outside the U.S. 
 1.27 “IP” means intellectual property. 
 1.28
“Know-How” means any proprietary technical or other information whether patentable or not and whether in written or verbal form, including technology, experience, formulae, concepts, discoveries, trade secrets, inventions,
modifications, improvements, data (including all chemical, preclinical, pharmacological, clinical, pharmacokinetic, toxicological, analytical and quality control data), results, designs, ideas, analyses, methods, techniques, assays, research plans,
procedures, tests, processes (including manufacturing processes, specifications and techniques), laboratory records, reports, summaries, and information contained in submissions to, and information from, regulatory authorities, but excluding any of
the foregoing to the extent described or claimed in any Patents. 

  
 *** INDICATES MATERIAL
THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.

  
 4 

			
	CONFIDENTIAL	  	Execution Copy

  

 1.29 “Licensed Technology” means Potelligent® CHOK1SV in combination with the Transfection Supplements System, the Vectors and related Licensor Know-How and
Licensor Patents, including Licensor Know-How related to (i) ***; (ii) protein expression, production or purification methods relating to the ***; (iii) therapeutic compositions, formulations or uses of, and other modifications to
***; and (iv) ***. 
 1.30 “Licensee Improvement” means any invention, discovery, development or other intellectual
property (including all Patent, Know-How and other intellectual property rights therein) *** made by or under authority of Licensee during the Term in conducting the Activities contemplated by this Agreement. 

1.31 “Licensor IP” means the Licensor Know-How and the Licensor Patents. 

1.32 “Licensor Know-How” means Know-How owned or Controlled by Licensor that relates to the Licensed Technology and that is
necessary or reasonably useful to Licensee’s use of the Licensed Technology pursuant to this Agreement and is provided to Licensee hereunder. 
 1.33 “Licensor Patents” means the Patents Controlled by Licensor that are set out in Exhibit 1, as well as all continuations, continuations-in-part, divisionals,
provisionals or any substitute applications with respect to the Patents set out in Exhibit 1, any patent issued with respect to any such patent applications set out in Exhibit 1, and all foreign counterparts of any of the foregoing, to
the extent that such Patents relate to and are necessary or reasonably useful to Licensee’s use of the Licensed Technology pursuant to this Agreement, including for researching, developing, commercializing, making, having made, using,
importing, having imported, exporting, having exported, having sold, offering for sale, selling or otherwise disposing of a Product pursuant to this Agreement. *** Exhibit 1 shall be amended and updated by Licensor from time to time as
continuations, continuations-in-part and divisional applications arise or as applications are amended or abandoned. 
 1.34
“Lonza Royalties” has the meaning set forth in Section 6.5.2. 
 1.35 “Major Market” means
***. 
 1.36 “Milestone Payments” means the payments set forth in Section 6.4. 

1.37 “Net Sales” means, with respect to a Product, the price invoiced by Licensee or any Sublicensee for sales of such Product to
independent, unrelated Third Parties in bona fide arms’ length transactions in the Territory (“Gross Sales”), less the following (to the extent applicable): 

(i) normal and customary trade, cash and quantity, prompt settlement or similar discounts (including chargebacks and allowances) actually
allowed with respect to the sale of such Product; 

  
 *** INDICATES MATERIAL
THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.

  
 5 

			
	CONFIDENTIAL	  	Execution Copy

  

 (ii) credits, deductions and allowances given or made for price adjustments, outdating,
billing errors, recalls or rejection or return of a previously sold Product; 
 (iii) taxes, duties or other governmental
charges imposed or levied on the sale of such Product or measured by the billing amount for such Product (excluding income and franchise taxes), to the extent not reimbursed by a Third Party; 

(iv) charges for packing, shipping, postage, handling, transportation, importation, freight, customs duties and insurance related to the
distribution of such Product; 
 (v) bad debts if and when actually written off or allowed; and 

(vi) rebates, reimbursements, fees or similar payments to (i) wholesalers and other distributors, pharmacies and other retailers,
buying groups (including group purchasing organizations), health care insurance carriers, pharmacy benefit management companies, health maintenance organizations, governmental authorities, or other institutions or health care organizations; or
(ii) to patients and other Third Parties arising in connection with any program applicable to a Product under which Licensee or its Sublicensees provides to low income, uninsured or other patients the opportunity to obtain Products at no cost
or reduced cost. 
 Sales between Licensee and any of its Sublicensees shall be excluded from the computation of Net Sales if such sales are not
intended for end use, but Net Sales shall include the subsequent final sales to Third Parties by any such Sublicensees. If a sale, transfer or other disposition with respect to the Product involves consideration other than cash or is not at
arm’s length, then the Net Sales from such sale, transfer or other disposition shall be the fair market value, which shall mean the selling party’s average sales price for the calendar quarter in the country where such sale, transfer or
other disposition took place (“Average Sales Price”), provided that if there were only de minimis cash sales in such country, at the fair market value as determined in good faith based on the Average Sales Price in
comparable markets. 
 In the event a Product is sold in any country in the form of a Combination Product (as defined herein below), Gross Sales
of the Product shall be determined by multiplying the actual Gross Sales of such Combination Product by the fraction A/(A + B), where A is the invoice price of the Product containing an Antibody or a set of Antibodies alone, if sold separately, and
B is the invoice price of (a) any other therapeutically active ingredient or drug, (b) any healthcare-related device, test or kit approved for insurance reimbursement in at least one Major Market, or (c) biological product (each a
“Non-Product Component”) in the Combination Product, if sold separately, in each case in the same country in the equivalent dosage or unit as in the Combination Product. If, on a country-by-country basis, the Non-Product Components
in a Combination Product are not sold separately in such country, Gross Sales of the Product shall be calculated by multiplying the actual Gross Sales of such Combination Product by the fraction A/C where A is the invoice price of the Product
containing an Antibody or a set of Antibodies alone if sold separately, 

  
 *** INDICATES MATERIAL
THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.

  
 6 

			
	CONFIDENTIAL	  	Execution Copy

  

 
and C is the invoice price of the Combination Product, in each case in the same country and in the equivalent dosage or unit as in the Combination Product. If, on a country-by-country basis,
Product component of a Combination Product is not sold separately in such country, but the Non-Product Component(s) are sold separately, Gross Sales shall be calculated by multiplying actual Gross Sales of such Combination Product by the fraction
(C-B)/C where B is the invoice price of the Non-Product Components, and C is the invoice price of the Combination Product, in each case in the same country and in the equivalent dosage or unit as in the Combination Product. If, on a
country-by-country basis, neither the Product containing an Antibody or a set of Antibodies alone nor the other Non-Product Component(s) of the Combination Product are sold separately in such country, Gross Sales, for such Combination Product shall
be determined by the Parties in good faith reasonably reflect the fair market value of the contribution of such Product in the Combination Product to the total fair market value of such Combination Product. 

For purposes of this definition, the term “Combination Product” means: (i) a product that contains both a Product and one or more
other therapeutically active ingredients that are not Antibodies, which are not attached or linked to such Antibodies alone; (ii) a product consisting of one or more separate products packaged together with a Product in a single package or as a
unit; or (iii) a drug, device, test, kit or biological product packaged separately that is sold as a unit with a Product. 

Notwithstanding the foregoing, Net Sales shall not include amounts (whether actually existing or deemed to exist for purposes of calculation) for
Products distributed for ***. 
 Net Sales will be calculated in accordance with GAAP consistently applied. 

1.38 “Patents” means all patents and patent applications and all patent applications filed therefrom, including any continuation,
continuation-in-part, divisional, provisional or any substitute applications, and any patent issued with respect to any such patent applications, any reissue, reexamination, renewal, revalidation, adjustment or extension (including any patent term
extension or supplemental patent certificate) of any such patent, and any confirmation patent or registration patent or patent of addition based on any such patent or patent application, and all foreign counterparts of any of the foregoing.

 1.39 “Phase I Clinical Trial” means a human clinical trial in any country that is intended to collect data on safety
of a Product for a particular indication or indications in patients with the disease or indication under study that would satisfy the requirements of 21 CFR §312.21(a) or its non-U.S. equivalent. 

1.40 “Phase II Clinical Trial” means a human clinical trial in any country that is intended to collect data on dosage and
evaluate the safety and the effectiveness of a Product for a particular indication or indications in patients with the disease or indication under study that would satisfy the requirements of 21 CFR §312.21(b) or its non-U.S. equivalent.

  
 *** INDICATES MATERIAL
THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.

  
 7 

			
	CONFIDENTIAL	  	Execution Copy

  

 1.41 “Phase III Clinical Trial” means a human clinical trial in any country that
is intended to be a pivotal trial the result of which would be used to establish safety and efficacy of a Product as a basis for a BLA that would satisfy the requirements of 21 CFR §312.21(c) or its non-U.S. equivalent. 

1.42 “Potelligent® CHOK1SV” means the FUT8 (-/-) knock-out CHOK1SV Cell Line jointly created by Lonza’s Affiliate, Lonza Biologics plc, and BioWa’s Affiliate, Kyowa
Hakko Kirin Co., Ltd., by combining the CHOK1SV Cell Line and the Potelligent® Technology. 

1.43 “Potelligent® Technology” means BioWa’s proprietary technology directly relating to the use of the cells which produce Antibodies with enhanced ADCC activity by
reducing the amount of fucose linked to the carbohydrate chain (“Potelligent® Cells”),
including (i) Potelligent® Cells; (ii) ***; (iii) protein expression, production or purification
methods; (iv) therapeutic compositions, formulations or uses of, and other modifications to, ***; and (v) ***. 
 1.44
“Product” means any composition or formulation owned or Controlled by Licensee containing or comprising, either alone or in combination with other active or inactive ingredients, an Antibody to the Commercial Target obtained
through use of the Licensed Technology. 
 1.45 “Progress Report” has the meaning set forth in Article 5. 

1.46 ***. 
 1.47
“Strategic Partner” means a Third Party with whom Licensee has entered into a contractual relationship (i) to identify a therapeutic target or (ii) to collaborate in the performance of research, development or
commercialization of a Product. In no event may any entity that is primarily a Competing Contract Manufacturer be deemed a Strategic Partner for the purposes of this Agreement. 
 1.48 “Sublicensee” means any Third Party (including, where appropriate, a Strategic Partner) or an Affiliate of Licensee, to whom Licensee has granted any of its rights under
Section 2.1. 
 1.49 ***. 
 1.50 “Target” means a polypeptide, a carbohydrate chain, or any other molecule to which an Antibody binds or which an Antibody modulates. 

  
 *** INDICATES MATERIAL
THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.

  
 8 

			
	CONFIDENTIAL	  	Execution Copy

  

 1.51 “Term” has the meaning set forth in Section 7.1. 

1.52 “Territory” means all countries and territories in the world. 
 1.53 “Third Party” means any entity other than Licensee, Licensor and their respective Affiliates. 
 1.54 “Transfected Cells” means Potelligent®
CHOK1SV cells transfected by Licensee with recombinant DNA encoding a monoclonal antibody. 
 1.55 “Transfection
Supplements” means the supplement solution set out in Exhibit 3. 
 1.56 “Transfection Supplements
Know-How” means any Know-How owned or Controlled by Licensor specifically relating to the Transfection Supplements, as set out in Exhibit 3. 
 1.57 “Transfection Supplements System” means the Transfection Supplements and Transfection Supplements Know-How, used either in combination or individually. 

1.58 “U.S.”, “USA” and “United States” means the United States of America, including all
commonwealths, territories, and possessions of the United States of America. 
 1.59 “Valid Claim” means an issued and
unexpired claim of a Licensor Patent that has not been canceled, revoked, withdrawn, or rejected and has not lapsed or become abandoned or been declared invalid, unpatentable or unenforceable or been revoked by a patent office, a court or other
governmental agency of competent jurisdiction from which no appeal can be or has been taken and which claim has not been disclaimed, denied or admitted to be invalid or unenforceable through reissue, re-examination, opposition or disclaimer or
otherwise, or lost in an interference proceeding. 
 1.60 “Vectors” means Lonza’s vectors identified in
Section 3.1(a). 
 ARTICLE 2—LICENSE GRANT AND COVENANTS 

2.1 License Grant to Licensee. Subject to the terms and conditions of this Agreement, Licensor hereby grants to Licensee a non-exclusive,
fee-bearing license in and to the Licensor IP, with the limited right to sublicense in accordance with Section 2.2, to research, develop, commercialize, make, have made, use, import, have imported, export, have exported, sell, have sold, offer
for sale and otherwise dispose of any and all Products in the Field in the Territory with respect to the Commercial Target (“Commercial License”). 
 2.2 Sublicense. Subject to the provisions of Section 2.7, Licensee may sublicense its rights under Section 2.1 to Third Parties or Licensee’s Affiliates and any such sublicenses
shall be granted pursuant to the terms and conditions set forth in Sections 2.2.1 to 2.2.4. 

  
 *** INDICATES MATERIAL
THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.

  
 9 

			
	CONFIDENTIAL	  	Execution Copy

  

 2.2.1 Sublicense rights shall not include the ***, except that: 

(a) Licensee may *** and *** to *** with prior written notice to Licensor of such transfer, solely for the purpose of conducting the
Activities as provided in this Agreement; and 
 (b) Licensee may *** and *** to *** solely for the purpose of ***, subject to
the terms of this Agreement. Licensee shall not *** any other ***, as listed in Section ***, except for any *** necessary for the *** of ***. 
 2.2.2 Prior to entering into a sublicense agreement with a proposed Sublicensee, Licensee shall ***. Licensee shall include in *** a certification that such sublicense will be granted expressly
subject to the terms of this Agreement and that Licensee will comply with the requirements of Section 2.1 and this Section 2.2 in relation to the grant of such sublicense. Licensor’s receipt of such notification, however, shall not
constitute a waiver of any right of Licensor or obligation of Licensee under this Agreement. 
 2.2.3
In each sublicense agreement, Licensee shall require the Sublicensee (a) not to use Potelligent®
CHOK1SV, Transfected Cells or Licensor Know-How for any purpose other than described in this Section 2.2 (b) not to offer for sale, sell, transfer or otherwise distribute Potelligent® CHOK1SV, Transfected Cells or Licensor Know-How to any other Third Party except as directed by Licensee in accordance with the terms of this Agreement; (c) to be
bound by confidentiality and non-use obligations no less strict than provided in this Agreement; and (d) ***. 
 2.3 Performance by
Sublicensees. Licensee’s execution of a sublicense agreement shall not relieve Licensee of any of its obligations under this Agreement. Licensee shall remain jointly and severally liable to Licensor for any performance or non-performance of
a Sublicensee that would be a breach of this Agreement if performed or omitted by Licensee and Licensee shall be deemed to be in breach of this Agreement as a result of such Sublicensee performance or nonperformance, except for those circumstances
in which such Sublicensee(s)’ performance or non-performance is capable of cure by Licensee, and Licensee promptly so cures. 
 2.4
Licensor’s Rights. Except for the rights granted to Licensee under this Agreement, all right, title and interest in and to the Licensed Technology shall at all times remain with and be vested in Licensor. Neither Licensee (including its
Affiliates) nor its Sublicensees shall use the Licensed Technology for any purpose other than as expressly granted to Licensee under this Agreement. 
 2.5 Third Party Rights and Licenses. Except for Licensor IP, Licensee shall be responsible for obtaining all rights from Third Parties or Licensor’s Affiliates that are necessary to research,
develop and commercialize the Products in the Field. 

  
 *** INDICATES MATERIAL
THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.

  
 10 

			
	CONFIDENTIAL	  	Execution Copy

  

 2.6 Permitted Uses of the Licensed Technology; Prohibition on Modifications or
Adaptations. Licensee’s use of the Licensed Technology is limited to inserting gene(s) coding for Licensee’s proprietary antibodies into the Vectors and then into Potelligent® CHOK1SV for the purpose of generating Antibodies and exercising the licenses set forth herein. Licensee hereby undertakes not to make any modifications or adaptations
to the *** except as explicitly provided under this Section 2.6. Licensee is specifically prohibited from performing any analysis, test, experiment or reverse-engineering of such ***; provided, however, that Licensee shall have
the right to conduct testing and analysis as reasonably necessary (i) to comply with standard cGMP manufacturing procedures and (ii) to develop cGMP manufacturing processes for Products, in each case for the purposes of supporting
regulatory filings or otherwise comply with regulatory requirements. 
 2.7 BioWa First Negotiation Right. 

2.7.1 *** Outlicense. If Licensee determines to seek to outlicense to a Third Party the development, manufacturing and
commercialization rights to a *** in ***, which outlicense does not include rights to the development, manufacturing and commercialization of a *** in *** (a “*** Outlicense”), then Licensee shall provide BioWa notice of such
determination, provided that Licensee shall have no obligation to provide BioWa such notice if Licensee shall have exercised its right to terminate the BioWa First Negotiation Right pursuant to Section 2.7.3. BioWa shall respond to
Licensee in writing, within *** (***) days of receipt of such notice, whether it desires to exercise its right of first negotiation with respect to such *** Outlicense (the “BioWa First Negotiation Right”). If BioWa timely exercises
the BioWa First Negotiation Right, then Licensee and BioWa shall negotiate in good faith the terms and conditions of a *** Outlicense. If requested by Licensee, BioWa shall first, including prior to receiving any due diligence information or term
sheet or draft agreement regarding the *** Outlicense, timely enter into a written non-disclosure agreement containing customary terms and conditions (an “NDA”), which shall be on a form of NDA acceptable to Licensee, to protect
confidential information Licensee may disclose to BioWa, including any due diligence information or term sheet or draft agreement regarding the *** Outlicense. If BioWa does not timely exercise the BioWa First Negotiation Right, then Licensee shall
have the right to enter into a *** Outlicense with any Third Party. 
 2.7.2 BioWa First Refusal Right. If BioWa
timely exercises the BioWa First Negotiation Right and BioWa and Licensee are unable to conclude negotiations and execute an agreement regarding a *** Outlicense within *** (***) months after the date on which BioWa timely exercises the BioWa First
Negotiation Right (the “ROFN Lapse Date”), then Licensee shall have the right to enter into a *** Outlicense with any Third Party. Notwithstanding the foregoing, if, after the ROFN Lapse Date, and provided that Licensee shall has
not exercised its right to terminate the BioWa First Refusal Right pursuant to Section 2.7.3, Licensee negotiates with a Third Party a bona fide *** Outlicense on aggregate economic terms more favorable than those offered to BioWa or by
BioWa under the BioWa First Negotiation Right option (which 

  
 *** INDICATES MATERIAL
THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.

  
 11 

			
	CONFIDENTIAL	  	Execution Copy

  

 
determination shall be made by Licensee in good faith and in its sole discretion, taking into account any upfront payments and the risk-adjusted time value of any milestone, royalty or other
payments that Licensee forecasts it would receive under such *** Outlicense), then BioWa shall have a right of first refusal, which is the right to match the terms and conditions on which Licensee proposes to accept an offer from such Third Party
(“BioWa First Refusal Right”). Licensee shall offer such terms and conditions to BioWa before entering into the respective *** Outlicense with such Third Party. BioWa shall respond to Licensee in writing, within *** (***) days of
receipt of Licensee’s information, whether it desires to accept the terms and conditions proposed by Licensee. If BioWa rejects such terms and conditions, or fails to respond within the period of *** (***) days, then BioWa’s First Refusal
Right to the *** Outlicense for the respective *** shall lapse, and Licensee shall have the full right to enter into a *** Outlicense with any Third Party. Licensee shall give notice to any Third Party with which it negotiates a *** Outlicense that
BioWa possesses the First Refusal Right described above. 
 2.7.3 Buyout of First Negotiation and First Refusal
Rights. Licensee shall have the right to terminate the BioWa First Negotiation Right and the BioWa First Refusal Right with respect to a *** by delivering a written notice of such termination to BioWa and paying to BioWa, within *** (***)
business days of such written notice, an amount equal to (i) *** U.S. Dollars (US $***), if such notice is delivered before Licensee *** for such *** in ***, or (ii) *** U.S. Dollars (US $***), if such notice is delivered after Licensee
*** for such *** in ***. If Licensee terminates the BioWa First Negotiation Right and the BioWa First Refusal Right with respect to a *** pursuant to this Section 2.7.3, Licensee shall thereafter (i) have no obligation to provide BioWa
notice of Licensee’s determination to seek to enter into a *** Outlicense with respect to such ***; and (ii) have no obligation to offer to BioWa the terms and conditions of any *** Outlicense with respect to such *** that Licensee may
have negotiated with any Third Party. 
 2.7.4 *** Plus Outlicense. If Licensee determines to seek to outlicense
to a Third Party the development, manufacturing and commercialization rights to a *** in any territory that includes *** and (i) at least *** or (ii) *** (a “*** Plus Outlicense”), Licensee would provide BioWa notice of
such determination. BioWa shall have no first negotiation right, right of first refusal or any similar right with respect to such *** Plus Outlicense. Notwithstanding the foregoing, if BioWa desires in good faith to evaluate entering into a *** Plus
Outlicense with Licensee, then Licensee shall provide BioWa with access to due diligence materials and make itself reasonably available for good faith discussions with BioWa to the same extent and on the same terms such access and availability are
extended to other Third Parties interested in such *** Plus Outlicense. Notwithstanding the foregoing, Licensee shall, including through its Affiliates, have the full right to research, develop, manufacture or commercialize any *** in ***.

  
 *** INDICATES MATERIAL
THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.

  
 12 

			
	CONFIDENTIAL	  	Execution Copy

  

 ARTICLE 3—MATERIAL TRANSFER AND OBLIGATIONS 

3.1 Provision of Materials. Following the signature of this Agreement by all Parties, Lonza shall supply to Licensee (ex-works Lonza’s
Affiliate’s premises, Slough, Berkshire, Incoterms 2000) the following: 
 (a) Vectors 

Approximately *** of vector ***. 
 Approximately *** of vector ***. 
 (b) Potelligent® CHOK1SV 
 *** vials of viable Potelligent® CHOK1SV. 

(c) Licensor Know-How 
 ***, and (iii) Vector nucleotide sequences. 
 In relation to the Transfection Supplements
System, Lonza shall (i) provide Licensee with details of at least one third party supplier from whom Licensee will be able to purchase Transfection Supplements, and (ii) supply Licensee with the Transfection Supplements Know-How. For the
avoidance of doubt, Licensee hereby confirms that Licensor may disclose to any such Third Party supplier the fact that Licensee and Licensor are parties to this Agreement and Licensor hereby confirms that Licensee may disclose to any such Third
Party supplier the fact that Licensee and Licensor are parties to this Agreement. 
 3.2 Provision of Technical Support. During the Term,
if requested by Licensee, Licensor shall provide technical assistance to Licensee in relation to the use of the Licensed Technology at a rate of *** U.S. Dollars (US $***) per employee-day and any travel and subsistence costs. This rate is valid for
*** (***) months from the Effective Date and is subject to review and adjustment thereafter. Any technical assistance Lonza shall provide on less than a full person day (defined as *** hours per day) shall be billed on a pro rata basis. 

3.3 Sole Uses of Licensed Technology. Licensee shall not use the *** for any purpose other than that permitted under this
Agreement. Upon transfection, Licensee shall (i) own all right, title and interest (subject to Licensee’s obligations hereunder and to rights retained by Licensor in the Licensor IP) in and to any Transfected Cells, including any research
cell bank, master cell bank, working cell bank or other cell bank created using such Transfected Cells; and (ii) have the right to use the Transfected Cells solely to research, develop, commercialize, make, have made, use, import, have
imported, export, have exported, sell, have sold, offer for sale, and otherwise dispose of Products pursuant to the terms and subject to the conditions of this Agreement. Except as specifically provided in this Agreement, Licensee shall not offer
for sale, sell, transfer or otherwise distribute *** to any Third Party. 

  
 *** INDICATES MATERIAL
THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.

  
 13 

			
	CONFIDENTIAL	  	Execution Copy

  

 ARTICLE 4—TARGET DESIGNATION 

4.1 Target Designation. *** Blank Rome LLP (the “Third Party Reviewer”), ***. The Third Party Reviewer maintains a list of
Targets (“Target List”) which are Targets that have been (i) designated by BioWa, its Affiliates or any Third Party licensees of BioWa (“Third Party Licensees”) on a non-exclusive basis, (ii) designated by
BioWa or its Affiliates exclusively for its or their own drug discovery programs, or (iii) to which BioWa has granted licenses or reserved exclusively for Third Parties, and so are not available for any other commercial license. The Targets
described in subsections (ii) and (iii) are designated “Excluded Targets”). The Third Party Reviewer has reviewed Licensee’s designated Commercial Target and advised the BioWa Representative that the Commercial Target
is not an Excluded Target. On that basis, the Commercial Target is available to Licensee as a Commercial Target for purposes of this Agreement and has been added to the Target List as a Commercial Target of Licensee. BioWa shall not cause the Third
Party Reviewer to reveal the identity of the Commercial Target (even if it is deemed to be an Excluded Target) to BioWa or to any Third Party at any time, except for the BioWa Representative. 
 4.2 Notification of Commencement of Phase I Clinical Trials. Within *** (***) days of Commencement of the first Phase I Clinical Trial for each Product, Licensee shall provide Licensor written
notice of such Commencement and such notice shall (i) specifically identify the Commercial Target for such Product and (ii) specifically identify the Product being developed. 

ARTICLE 5—PROGRESS REPORTS 
 During the Term, and subject to Licensee’s right not to disclose Licensee’s Confidential Information, including the identity of the Commercial Target, Licensee shall deliver to Licensor annual,
confidential, written progress reports, following the format set forth in Exhibit 2, of Activities conducted by Licensee and its Sublicensees in the preceding Calendar Year, including Licensee’s progress towards the achievement of
milestone events set forth in Section 6.4 (the “Progress Report”). The first Progress Report shall be due on ***, and subsequent Progress Reports on *** thereafter. 

  
 *** INDICATES MATERIAL
THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.

  
 14 

			
	CONFIDENTIAL	  	Execution Copy

  

 ARTICLE 6—FINANCIAL TERMS 

6.1 Lonza Technology Access Fee. In partial consideration of the rights and licenses granted herein, Licensee shall pay to Lonza a one-time
non-refundable, non-creditable technology access fee of *** U.S. Dollars (US $***) (“Technology Access Fee”). Licensee shall pay the Technology Access Fee within *** (***) days following execution of this Agreement. 

6.2 BioWa Commercial License Fee. In partial consideration of the rights and licenses granted herein, Licensee shall pay to BioWa an annual
nonrefundable, non-creditable commercial license fee of *** U.S. Dollars (US $***) (“BioWa Commercial License Fee”) until the anniversary of the Effective Date immediately preceding BioWa’s receipt of the first royalty payment
for a Product produced against the Commercial Target. Licensee shall pay the initial BioWa Commercial License Fee within *** (***) days following execution of this Agreement. The second and subsequent BioWa Commercial License Fees will be due ***
(***) days after each applicable anniversary of the Effective Date. Without prejudice to the payment obligation set forth in this Section 6.2, BioWa shall send to Licensee an invoice for each Commercial Licensee Fee on or within *** (***) days
before the relevant anniversary of the Effective Date. 
 6.3 Lonza Annual License Fee. In partial consideration of the rights and
licenses granted herein, Licensee shall pay to Lonza an annual, nonrefundable, non-creditable commercial license fee, ***, of (i) *** U.S. Dollars (US $***) for ***, or (ii) *** U.S. Dollars (US $***) for *** (“Lonza Annual License
Fee”). Licensee shall pay no Lonza Annual License Fee for ***. Licensee shall pay to Lonza the initial payment of the Lonza Annual License Fee following the *** for such Product, continuing on an annual basis until the end of the Term.
Payment for the second and subsequent Lonza Annual License Fees will be due *** (***) days after each applicable anniversary of the *** for such Product. Without prejudice to the payment obligation set forth in this Section 6.3, Lonza shall
send to Licensee an invoice for each Lonza Annual License Fee on or within *** (***) days before the relevant anniversary of the *** for such Product. 
 6.4 Milestone Payments. 
 6.4.1 BioWa Milestone
Payments. In partial consideration of the licenses granted herein, Licensee shall make the following non-refundable and non-creditable milestone payments to BioWa upon achievement of the first occurrence of the following milestone events by
Licensee or a Sublicensee: 
 (a) *** U.S. Dollars (US $***) upon Commencement of the first Phase I
Clinical Trial; 
 (b) *** U.S. Dollars (US $***) upon Commencement of the first Phase II Clinical Trial;

  
 *** INDICATES MATERIAL
THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.

  
 15 

			
	CONFIDENTIAL	  	Execution Copy

  

 (c) *** U.S. Dollars (US $***) upon Commencement of the first
Phase III Clinical Trial; 
 (d) *** U.S. Dollars (US $***) upon submission of the first BLA; 

(e) *** U.S. Dollars (US $***) upon first commercial sale of a Product in the first Major Market; 

(f) *** U.S. Dollars (US $***) upon first commercial sale of a Product in the second Major Market; 

(g) *** U.S. Dollars (US $***) upon the first achievement of global annual Net Sales of *** U.S. Dollars (US $***)
in a Calendar Year; 
 (h) *** U.S. Dollars (US $***) upon the first achievement of global annual Net
Sales of *** U.S. Dollars (US $***) in a Calendar Year; and 
 (i) *** U.S. Dollars (US $***) upon the
first achievement of global annual Net Sales of *** U.S. Dollars (US $***) in a Calendar Year. 
 6.4.2 Lonza
Milestone Payments. In partial consideration of the licenses granted herein, Licensee shall make the following non-refundable and non-creditable milestone payments to Lonza upon achievement of the first occurrence of the following milestone
events by Licensee or a Sublicensee: 
 (a) (i) for Product ***, *** U.S. Dollars (US $***) upon
Commencement of the first Phase I Clinical Trial or (ii) for Product ***, *** U.S. Dollars (US $***) upon Commencement of the first Phase I Clinical Trial; and 

(b) (i) for Product ***, *** U.S. Dollars (US $***) upon Commencement of the first Phase II Clinical Trial or
(ii) for Product ***, *** U.S. Dollars (US $***) upon Commencement of Phase II Clinical Trial. 
 6.5 Royalty Payments. 

6.5.1 BioWa Royalty Payments. During the Term and subject to Sections 6.5.3 and 6.5.4, Licensee shall pay to BioWa
royalties (the “BioWa Royalties”) on a Calendar Quarter basis and on a Product-by-Product and country-by-country basis with respect to Net Sales for such Product during such Calendar Quarter at the following rates: 

(a) *** percent (***%) of the portion of Net Sales for such Product during such Calendar Quarter to the extent that
total Net Sales in the Territory for such Product in such Calendar Year are less than *** U.S. Dollars (US $***); and 

  
 *** INDICATES MATERIAL
THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.

  
 16 

			
	CONFIDENTIAL	  	Execution Copy

  

 (b) *** percent (***%) of the portion of Net Sales for such
Product during such Calendar Quarter to the extent that total Net Sales in the Territory for such Product in such Calendar Year are equal to or exceed *** U.S. Dollars (US $***). 

6.5.2 Lonza Royalty Payments. During the Term and subject to Sections 6.5.3 and 6.5.4, Licensee shall pay to Lonza
royalties (the “Lonza Royalties”) on a Calendar Quarter basis and on a Product-by-Product basis with respect to Net Sales for such Product during such Calendar Quarter at the following rates: 

(a) In respect of Product ***, a royalty of *** percent (***%) of the Net Sales for such Product during such
Calendar Quarter. 
 (b) In respect of Product ***, a royalty of *** percent (***%) of the Net Sales for
such Product during such Calendar Quarter. 
 (c) In respect of Product ***, a royalty of *** percent
(***%) of the Net Sales for such Product during such Calendar Quarter. 
 6.5.3 Duration of Payments. On a
Product-by-Product basis and country-by-country basis, Licensee’s royalty payment obligations under this Section 6.5 shall commence upon the First Commercial Sale of such Product in such country and expire upon the later of: (i) the
date on which there is no longer a Valid Claim within the Licensor Patents in such country that covers such Product; or (ii) the tenth (10th) anniversary of the First Commercial Sale of such Product in a Major Market (“Royalty
Term”). After the expiration of the Royalty Term for a particular Product in a country within the Territory, the licenses granted to Licensee by Licensor under Section 2.1 shall become fully paid-up and perpetual licenses for such
Product in the Field in such country. 
 6.5.4 Royalty Reduction for Net Sales in Countries Without a Valid Claim.
In the event that during the Royalty Term there are Net Sales of a Product in a country in which there is no Valid Claim covering such Product, royalties otherwise due with respect to such Net Sales under Sections 6.5.1 and 6.5.2 shall be reduced by
*** percent (***%) for the duration of the Royalty Term. 
 6.6 Notification Obligations and Payment Dates for Milestone Payments and
Royalties. Licensee shall inform Licensor in writing within *** (***) days of achieving each milestone by Licensee or its Sublicensee under this Agreement. Licensee shall make the relevant Milestone Payment within *** (***) Business Days of
confirmation of achieving such milestone. All Royalty payments under Section 6.5 shall be due and payable quarterly and within *** (***) calendar days of the close of the Calendar Quarter during which the corresponding Net Sales are recognized.
Together with any such payment, Licensee shall deliver a report specifying in the aggregate and on a country-by-country basis: (i) total gross invoiced amount from sales of the Products by Licensee and its Sublicensees; (ii) amounts
deducted, to calculate Net Sales; (iii) Net 

  
 *** INDICATES MATERIAL
THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.

  
 17 

			
	CONFIDENTIAL	  	Execution Copy

  

 
Sales; and (iv) Royalties payable. For purposes of computing Royalty payments for Net Sales payable to Licensor made outside of the U.S., such royalties shall be converted into U.S. Dollars
by applying the rate of exchange quoted in the New York edition of The Wall Street Journal on the last Business Day of the applicable Calendar Quarter. 
 6.7 Late Payment. Any payments or portions thereof due to Licensor hereunder which are not paid when due shall bear interest equal to (i) the prime rate as reported by in the New York edition
of The Wall Street Journal on the date such payment is due, plus an additional *** percent (***%) per annum or (ii) if lower, the maximum rate permitted by law, calculated on the number of days such payment is delinquent. This
Section 6.7 shall in no way limit any other remedies available to Licensor for late payments. Failure to make any payments pursuant to the terms of this Agreement hereunder shall constitute a breach of this Agreement. 

6.8 Mode of Payment. 
 6.8.1 Mode of Payment to BioWa. All payments to BioWa hereunder shall be made in U.S. Dollars in the stated amount by wire transfer to such bank account as BioWa may from time to time
designate by notice in writing to Licensee. Until otherwise designated by notice, the fees payable to BioWa under this Article 6 shall be paid to ***, account number ***, ABA number ***. Payments shall be free and clear of any taxes, fees or
charges, to the extent applicable. 
 6.8.2 Mode of Payment to Lonza. All payments to Lonza hereunder shall be
made in U.S. Dollars in the stated amount by wire transfer to such bank account as Lonza may from time to time designate by notice in writing to Licensee. Until otherwise designated by notice, the fees payable to Lonza under this Article 6 shall be
paid to: account no. ***. 
 6.9 Records Retention and Audit.  

6.9.1 With respect to each Product, Licensee shall keep, and shall cause its Sublicensees, and their respective agents, to keep
for at least *** (***) years, complete, true and accurate books of accounts and records of all quantities of Products manufactured and sold (or otherwise distributed) in sufficient detail to confirm the accuracy of the Net Sales and royalty
calculations hereunder. 
 6.9.2 Upon reasonable prior written notice from Licensor, during the Term and for *** (***)
years thereafter, no more than once per twelve (12)-month period, Licensee shall permit an independent certified public accountant (the “Accountant”), appointed and paid by Licensor, and reasonably acceptable to Licensee, at
reasonable times during normal business hours and under a written confidentiality agreement between the Accountant and Licensee executed prior to the inspection, to examine these records solely to the extent reasonably necessary verify the accuracy
of the Net Sales and royalty calculations hereunder for any Calendar Year ending not more than *** (***) months prior to the date of such request. Upon completion of any 

  
 *** INDICATES MATERIAL
THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.

  
 18 

			
	CONFIDENTIAL	  	Execution Copy

  

 
investigation by the Accountant hereunder, the Accountant shall provide both Licensee and Licensor a written report disclosing whether the royalty reports submitted by Licensee are correct or
incorrect, whether the royalties paid are correct or incorrect, and in each case, the specific details concerning any discrepancies. 
 6.9.3 Any such investigation pursuant to this Section 6.9 shall be at the expense of Licensor, unless the Accountant’s investigation reveals a discrepancy in Licensor’s favor of more
than *** percent (***%), in which event Licensee shall reimburse Licensor for the Accountant’s fees in performing such investigation. If the Accountant’s investigation shows underpayment of royalties, Licensee shall promptly (but in no
event later than *** (***) days after Licensee’s receipt of the Accountant’s report so concluding) remit to Licensor the amount of such underpayment, and all such payments shall be subject to the accrual of interest pursuant to
Section 6.7. If the Accountant’s investigation shows overpayment of royalties, Licensor shall credit such overpayment to any subsequent amounts owed to Licensor by Licensee or, if Licensee has no future payment obligations under this
Agreement, then Licensor shall refund such overpayment and promptly pay such overpaid amount to Licensee. Licensee shall ensure that all Sublicensees comply with Licensee’s obligations under this Section 6.9. 

6.10 Tax Withholding. The Parties agree to cooperate with one another and use reasonable efforts to avoid or reduce tax withholding or similar
obligations in respect of royalties, milestone payments, and other payments made by Licensee to BioWa or Lonza under this Agreement. To the extent Licensee is required by applicable law to deduct and withhold taxes on any payment to BioWa or Lonza
under this Agreement, Licensee shall pay the amounts of such taxes to the proper governmental authority in a timely manner, and the sum payable to BioWa or Lonza shall be decreased by the same amount. BioWa and Lonza agree to provide to Licensee any
tax forms that may be reasonably necessary in order for Licensee to not withhold tax or to withhold tax at a reduced rate under an applicable bilateral income tax treaty. BioWa and Lonza shall use reasonable efforts to provide any such tax forms to
Licensee in advance of any applicable due date. Each Party shall provide the other with reasonable assistance to enable the recovery, as permitted by applicable law, of withholding taxes or similar obligations resulting from payments made under this
Agreement, such recovery to be for the benefit of BioWa or Lonza, as the case may be. 
 6.11 Blocked Payments. In the event that,
by reason of applicable laws or regulations in any country, it becomes impossible or illegal for Licensee or its Sublicensees to transfer, or have transferred on its or their behalf, royalties or other payments to Licensor, such royalties or other
payments shall be deposited in local currency in the relevant country to the credit of Licensor in a recognized banking institution designated by Licensor or, if none is designated by Licensor within a period of *** (***) days, in a recognized
banking institution selected by Licensee or its Sublicensees, as the case may be, and identified in a written notice to Licensor. 

  
 *** INDICATES MATERIAL
THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.

  
 19 

			
	CONFIDENTIAL	  	Execution Copy

  

 ARTICLE 7—TERM AND TERMINATION 

7.1 Term and Expiration. This Agreement shall become effective on the Effective Date and, unless earlier terminated pursuant to this Article 7,
shall remain in full force and effect until there are no remaining Royalty payment obligations with respect to any Product in any country (the “Term”). 
 7.2 Termination at Will by Licensee. Licensee shall have the right to terminate this Agreement in its entirety for any reason upon *** (***) days prior written notice to Licensor. Upon termination
in accordance with this Section 7.2, the licenses granted by Licensor pursuant to Article 2 shall terminate. Licensee shall remain obligated for all payments due at the time of such notice and for any continuing obligations otherwise surviving
and owed under this Agreement pursuant to Section 7.9. 
 7.3 Termination for Breach. Without prejudice to any other remedies that
may be available under this Agreement, in the event that Licensee, on the one hand, or Licensor, on the other hand, believes that the other has materially breached this Agreement, then such Party may deliver notice of such breach to the allegedly
breaching Party. The allegedly breaching Party shall have *** (***) days from such notice to dispute such breach or commence a cure of the breach, and shall have *** (***) days from such notice to complete such cure (or such longer period as may be
agreed by the Parties if the breaching Party is exercising diligent efforts to cure such breach and *** (***) days is insufficient to cure such breach), except when the breach is a non-payment of payments owed, in which case such breach must be
disputed or cured within *** (***) days from the date of such breach notice. If the Party receiving notice of an alleged breach fails to cure, or fails to dispute, the alleged breach within the periods set forth above, then, subject to the rest of
this Section 7.3, the Party originally delivering the notice of breach may terminate this Agreement in its entirety, effective on written notice of termination to the other Party. If the allegedly breaching Party in good faith disputes such
alleged material breach or disputes the failure to cure or remedy such material breach and provides written notice of that dispute to the other Party within the period set forth above, the matter will be addressed under the dispute resolution
provisions in Article 12; and the notifying Party may not terminate this Agreement until the date that it has been determined under Article 12 that the allegedly breaching Party is in material breach of this Agreement. Upon such date and for a
period of *** (***) days thereafter, this Agreement may be terminated by the non-breaching Party by written notice to the breaching Party. 

7.4 Termination for Challenging Licensor Patents. If at any time during the Term, Licensee knowingly opposes or knowingly assists any Third Party,
whether directly or indirectly, in opposing, the grant of letters patent or any patent application within any of the Licensor Patent Rights, or disputes or knowingly assists any Third Party, whether directly or indirectly, in disputing the validity
of any Patent within any of the Licensor Patents or any of the claims thereof, Licensor shall be entitled, at any time thereafter, to terminate the licenses granted hereunder forthwith upon *** (***) days prior written notice to Licensee. The
provisions of this Section 7.4 shall not apply to those situations in which Licensee, under compulsory process of law, is required to assist a Third Party. 

  
 *** INDICATES MATERIAL
THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.

  
 20 

			
	CONFIDENTIAL	  	Execution Copy

  

 7.5 Termination for Insolvency. Either Licensor or Licensee may terminate this Agreement by
written notice with immediate effect if the other is judicially declared to be insolvent, makes an assignment for the benefit of creditors, is the subject of proceedings in a voluntary or involuntary bankruptcy proceeding instituted on behalf of or
against such Party (except for involuntary bankruptcies that are dismissed within *** (***) days), or has a receiver or trustee appointed for substantially all of its property. 
 7.6 Accrued Rights and Obligations. Termination or expiration of this Agreement, in whole or in part, for any reason shall not (a) release any Licensor or Licensee from any liability which, at
the time of such termination or expiration, has already accrued or which is attributable to a period prior to such termination or expiration or (b) preclude any Licensor or Licensee from pursuing any rights and remedies it may have hereunder,
or at law or in equity, with respect to any breach of, or default under, this Agreement. Licensor or Licensee understand and agree that monetary damages may not be a sufficient remedy for a breach of this Agreement and that Licensor or Licensee may
be entitled to injunctive relief as a partial remedy for any such breach. 
 7.7 Inventory on Hand. Upon termination (but not expiration)
of this Agreement by Licensee for any reason, Licensee and its Sublicensees may complete any production batches of Product in process at the date of such termination and sell or otherwise distribute the inventory of any Product then on hand until
the ***. All such sale or distribution shall be subject to the relevant terms of this Agreement (including the payment of royalties thereon). 
 7.8 Destruction of Biological Materials. Upon termination (but not expiration) of this Agreement by Licensee pursuant to Section 7.2 or by Licensor pursuant to Section 7.3, 7.4 or 7.5,
Licensee and its Sublicensees shall (i) promptly destroy all Transfected Cells, as well as all Antibodies, and (ii) ***, promptly destroy all Potelligent® CHOK1SV, Vectors or Transfection Supplements and an officer of Licensee shall provide Licensor with a written certification to such effect; provided,
however, that in the event Licensor terminates this Agreement pursuant to Section 7.3 for Licensee’s breach of its obligations under Sections 2.6 or 3.3, Licensee shall have no continuing right or license to use Potelligent® CHOK1SV, Vectors or Transfection Supplements pursuant to this Agreement or a ***. Notwithstanding the foregoing, the
Parties may continue to exercise the rights granted in Section 7.7. 
 7.9 Licenses. The license(s) granted to Licensee in this
Agreement shall terminate upon any termination of this Agreement and, in such event, Licensee shall cease, and cause its Sublicensees to cease, exercising any such licenses with respect to the use of Licensor IP Rights or the Licensed Technology for
any purposes, including but not limited to, the research, development, 

  
 *** INDICATES MATERIAL
THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.

  
 21 

			
	CONFIDENTIAL	  	Execution Copy

  

 
manufacturing and commercialization of any Product. Notwithstanding the foregoing, the Parties may continue to exercise the rights granted in Section 7.7. For clarity, provided that Licensor
shall not have terminated this Agreement pursuant to Section 7.3 for Licensee’s breach of its obligations under Sections 2.6 or 3.3, any termination of this Agreement or the licenses granted hereunder will have no effect on ***.

 7.10 Survival. The following provisions of this Agreement shall survive expiration or termination of this Agreement: Article 1;
Section 2.1 (to the extent any license has become fully paid-up and perpetual pursuant to Section 6.5.3); Section 2.3 (regarding performance by Sublicensees); Section 2.4 (regarding Licensor’s retained rights);
Section 2.6 (regarding limits on Licensee’s use of the Licensed Technology); Section 3.3 (regarding sole uses of Licensed Technology); Article 6 (regarding payment obligations incurred prior to termination or expiration, record
retention and audit rights); Section 6.5.3; Sections 7.6 through 7.9; Section 8.1 (regarding the ownership of IP rights); Section 8.2 (regarding Patent prosecution); Article 9 (regarding confidentiality); Sections 10.4, 10.5 and 10.6
(regarding warranty disclaimers); Article 11 (regarding indemnifications and limitation of liability); Article 12 (regarding dispute resolution); and Article 13 (regarding miscellaneous provisions). 

ARTICLE 8—INTELLECTUAL PROPERTY 
 8.1 Ownership of Intellectual Property. 
 8.1.1 General. ***
shall be owned by Licensor, and Licensee hereby assigns to Licensor its entire right, title and interest in and to any ***. Licensee shall disclose or cause to be disclosed to Licensor all *** made by or under authority of Licensee or its
Sublicensees pursuant to the Activities contemplated by this Agreement during the Term. Licensee (including its Sublicensees) shall maintain records in sufficient detail and in good scientific manner to properly reflect all work done and results
achieved in connection with *** hereunder. Licensee (including its Sublicensees) shall promptly execute all documents and take all such other reasonable actions as may be reasonably requested to enable Licensor to prosecute and maintain Patents on
the ***. 
 8.1.2 ***. ***, shall be owned solely and exclusively by Licensee. For clarity, the *** and any
invention, discovery, development or other intellectual property (including all Patent, Know-How and other intellectual property rights therein) that relate to the *** that are made by or under authority of Licensee are not Licensed Technology, and
not subject to either Section 8.1.1 or 8.1.3. 
 8.1.3 ***. 

  
 *** INDICATES MATERIAL
THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.

  
 22 

			
	CONFIDENTIAL	  	Execution Copy

  

 8.2 Patent Prosecution. As between Licensor and Licensee, Licensor shall have the sole right, at
its expense, to control the Prosecution and Maintenance of the Licensor Patents ***, using counsel of its choice, and Licensee shall have the sole right, at its expense, to control the Prosecution and Maintenance of any Patents on Licensee
Improvements owned by Licensee as provided under Section 8.1.2, using counsel of its choice. As used in this Article 8, “Prosecution and Maintenance” (and “Prosecute and Maintain”) shall mean the preparing, filing,
prosecuting and maintenance of such Patents, as well as re-examinations, reissues, post-grant reviews, requests for patent term extensions and the like with respect to such Patents, together with the conduct of interferences, the defense of
oppositions, appeals or petitions to any Board of Appeals in a patent office, appeals to any court of any patent office decisions and other similar proceedings with respect to such Patents. 
 8.3 Infringement by Third Party. Subject to the provisions of this Section 8.3, in the event that Licensee has knowledge that any Licensor Patent is being infringed by a Third Party or is
subject to a declaratory judgment action arising from such infringement, Licensee shall promptly notify Licensor. Licensor shall have the sole right (but not the obligation) to enforce the Licensor Patents covering the Licensed Technology (an
“Enforcement Action”). Licensee shall reasonably cooperate with Licensor in all such actions or proceedings at Licensor’s cost and expense. Licensee agrees to be joined as a plaintiff, if necessary and required by applicable
law, and shall provide all reasonable cooperation (including any necessary use of its name) required to prosecute such litigation at Licensor’s cost and expense. Licensor shall have the sole benefit of any damages collected from any such
Enforcement Action. 
 8.4 Third Party Infringement Claims. Licensee shall promptly notify Licensor in writing of any written claims that
Licensee’s use of the Licensor Patents or Licensor Know-How infringes or improperly or unlawfully uses the proprietary rights of any Third Party. Licensor shall have the sole right and the obligation to use commercially reasonable efforts to
take such steps and proceedings and to do all other acts and things as may in Licensor’s sole discretion be necessary to defend such claims and Licensee shall permit Licensor to have the sole conduct of any such steps and proceedings, including
the right to settle them. Licensee hereby agrees to use commercially reasonable efforts to cooperate fully with Licensor at Licensor’s cost and expense. Licensor shall be entitled to retain any and all damages received from such proceedings.

 8.5 Product Markings and Trademarks. Each Product marketed and sold by Licensee or its Sublicensees under this
Agreement shall be marked with all patent and other intellectual property notices relating to the Licensor Patents as may be required by applicable law. Subject to the terms and conditions of this Agreement, Licensor hereby grants to Licensee a
non-exclusive, revocable license, with the limited right to sublicense to its Sublicensees, to use and display the
“Potelligent® CHOK1SVTM” trademark solely for marking the Products, if required, under this
Section 8.5. 

  
 *** INDICATES MATERIAL
THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.

  
 23 

			
	CONFIDENTIAL	  	Execution Copy

  

 ARTICLE 9—CONFIDENTIALITY; PUBLICATION AND REGULATORY FILINGS 

9.1 Confidential Information. The Parties recognize that each Party’s Confidential Information constitutes highly valuable and proprietary
assets of the disclosing Party. Each Party agrees that, notwithstanding the termination or expiration of this Agreement, the receiving Party shall maintain all Confidential Information of a disclosing Party in confidence and shall not publish,
disseminate or otherwise disclose a disclosing Party’s Confidential Information to any Third Party, nor use any Confidential Information of a disclosing Party, without the written consent of the disclosing Party, except for the purpose of this
Agreement as provided in this Article 9. Notwithstanding the foregoing, the receiving Party may disclose and disseminate Confidential Information of the disclosing Party only to those officers, employees, directors, auditors, legal counsel or
contractors of the receiving Party and such receiving Party’s Affiliates and Sublicensees who have a bona fide need to know such Confidential Information for the purposes of this Agreement, and only after such officers, employees,
directors, auditors, legal counsel or contractors have been advised of the confidential nature of such information and are bound, whether by fiduciary obligation or in writing, as appropriate, by an obligation of confidentiality and non-use under
terms substantially similar to, and as protective of the disclosing Party as, the confidentiality and non-use obligations in this Agreement. 

9.2 Permitted Use and Disclosures. Each receiving Party may (i) use Confidential Information of a disclosing Party to exercise its rights or
perform its obligations hereunder, or (ii) use or disclose Confidential Information of a disclosing Party to the extent such use or disclosure is reasonably necessary in (a) complying with applicable governmental regulations or otherwise
submitting information to governmental authorities, (b) conducting clinical trials or applying for regulatory approvals, and (c) negotiating or making a permitted sublicense, provided that if a receiving Party is required to make
any such disclosure of a disclosing Party’s Confidential Information pursuant to clause (ii)(a), it shall make commercially reasonable efforts to: (w) give prompt written notice to the disclosing Party of the proposed disclosure to the
relevant governmental authority, and allow the disclosing Party to object to all or any portion of the disclosure before it is disclosed; (x) if advance notice is not possible, provide written notice of disclosure immediately thereafter;
(y) to the extent possible, minimize the extent of such disclosure; and (z) secure confidential treatment of such information prior to its disclosure (whether through protective orders or otherwise), it being understood that any
information so disclosed shall otherwise remain subject to the limitations on use and disclosure hereunder. The Party proposing to disclose any Confidential Information under this provision shall take into reasonable consideration any comments and
objections raised by the disclosing Party. 

  
 *** INDICATES MATERIAL
THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.

  
 24 

			
	CONFIDENTIAL	  	Execution Copy

  

 9.3 Press Releases. The text of any press release or other communication to be published by or
presented in the media concerning the subject matter of this Agreement shall require the prior written approval of all Parties, except as may be required by law or regulation. ***. 
 9.4 Disclosures Required by Law. If a public disclosure is required by law, rule or regulation, including in a filing with the Securities and Exchange Commission, the disclosing Party shall provide
copies of the disclosure reasonably in advance of such filing or other disclosure, but not later than *** (***) Business Days prior to the filing, for a non-disclosing Party’s prior review and comment and to allow a non-disclosing Party a
reasonable time to object to any such disclosure or to request confidential treatment thereof. 
 9.5 Review of Proposed Publications,
Presentations or Patent Applications. No Party shall publish any manuscript, abstract, specification, text or any other material (“Materials”) that includes information about this Agreement or another Party’s Confidential
Information without providing a copy of the Materials to such other Party for such Party’s review and obtaining such other Party’s prior written consent to the publication of such Party’s Confidential Information pursuant to this
Section 9.5. For clarity, this Section 9.5 shall not limit Licensee from publishing its research or clinical results relating to any Product (including the results of any clinical trial), provided that Licensee may not disclose
another Party’s Confidential Information. Without the prior written consent of Licensor, Licensee shall not publish any Materials that disclose Confidential Information of Licensor. Without the prior written consent of Licensee, Licensor shall
not publish any Materials relating to any Product or any Materials that disclose Confidential Information of Licensee. 
 A receiving Party
shall review any such Materials provided to it by the publishing Party to determine if Confidential Information of such receiving Party is or may be disclosed. A reviewing Party shall notify the publishing Party in writing within *** (***) calendar
days after receipt of the proposed publication if the receiving Party determines that Confidential Information of the reviewing Party is or may be disclosed and, if so, identify such Confidential Information that is or may be disclosed. If it is
determined that Confidential Information of a reviewing Party is being disclosed, the publishing Party shall comply with any request to remove such Confidential Information from the proposed publication to avoid such disclosure. 

If the reviewing Party has a reasonable, bona fide belief that the reviewing Party may file a patent application with respect to the subject
matter to be disclosed in the Materials, the reviewing Party shall notify the publishing Party of such belief and identify such subject matter in writing within *** (***) calendar days after receipt of the proposed publication and the publishing
Party shall either (i) delay its submission for publication or presentation of such Materials for a period not to exceed *** (***) calendar days from the reviewing Party’s receipt of the proposed publication to allow the reviewing Party
time to file one or more patent applications with respect to such subject matter or (ii) the publishing Party shall remove such subject matter from the Materials prior to submission for publication or presentation. In the event that the delay
needed to file any necessary patent application exceeds the ***-day period, the Parties shall discuss the need for obtaining an extension of the publication delay beyond the ***-day period. 

  
 *** INDICATES MATERIAL
THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.

  
 25 

			
	CONFIDENTIAL	  	Execution Copy

  

 To the extent that any of the terms of or the application of this Section 9.5 conflict with any of
the terms set forth in Section 9.2 or 9.4, the terms of Section 9.2 or 9.4, respectively, shall govern. 
 9.6 Confidential
Terms. Except as expressly permitted in this Agreement, no Party shall disclose any terms of this Agreement to any Third Party without the prior written consent of the other Parties; except that such consent shall not be required for disclosure
to actual or prospective investors or acquirers or to a Party’s accountants, attorneys and other professional advisors (provided that such disclosures shall be subject to continued confidentiality obligations at least as strict as are set forth
herein). Notwithstanding the foregoing, Licensor agrees that Licensee may publicly disclose that it has entered into this Agreement and that Licensor has licensed the rights hereunder to Licensee, but Licensee shall not disclose the specific terms
and conditions of this Agreement to any Third Party without the prior written consent of Licensor. 
 9.7 Return or Destruction of
Confidential Information. Upon termination of this Agreement, Licensor and Licensee shall each, at the disclosing Party’s sole discretion, either promptly return to the other all Confidential Information of the other (including any copies
or extracts thereof) or destroy all such Confidential Information and all tangible items comprising, bearing or containing any such Confidential Information and provide a written certification of such destruction; provided, however,
that each Party may retain one (1) copy of such Confidential Information for archival purposes and for ensuring compliance with this Article 9. Notwithstanding the foregoing and for clarity, after the expiration of the Royalty Term for any
Product in a country within the Territory, Licensee shall have no obligation to under this Section 9.7 to return or destroy any Licensor Know-How or Licensed Technology that is necessary or reasonably useful to Licensee’s use of its fully
paid-up, irrevocable and perpetual licenses for such Product in the Field in such country. ***. 
 9.8 Licensee
Regulatory Filings. Licensor shall provide to Licensee a regulatory package containing relevant details on
Potelligent® CHOK1SV, including source, details of the cell history, relevant adventitious agent testing, and
generation of cell substrate, to support Product regulatory filings. Licensor shall support Licensee, as may be reasonably necessary, in Licensee’s making regulatory filings with respect to any Product and seeking regulatory approvals for
any such Product, including providing necessary documents, or other materials required by applicable law to make such regulatory filings or obtain such regulatory approvals, all such support to be at Licensee’s expense. 

  
 *** INDICATES MATERIAL
THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.

  
 26 

			
	CONFIDENTIAL	  	Execution Copy

  

 ARTICLE 10—REPRESENTATIONS, WARRANTIES AND COVENANTS 

10.1 Mutual Representations, Warranties and Covenants. Licensor and Licensee each warrants, represents and covenants to the other that:

 10.1.1 Organization. Such Party is duly organized and validly existing under the laws of its jurisdiction of
incorporation, and has full corporate power and authority to enter into this Agreement and to perform its obligations hereunder; 
 10.1.2 Authority. This Agreement has been duly authorized, executed and delivered by such Party and constitutes valid and binding obligations of such Party, enforceable in accordance with their
respective terms, subject to applicable bankruptcy, insolvency, reorganization, and other laws of general application limiting the enforcement of creditors’ rights; 
 10.1.3 Consents and Approvals. Such Party has obtained all necessary consents, approvals and authorizations of all governmental authorities and Third Parties required to be obtained by such Party
in connection with the execution of this Agreement; 
 10.1.4 No Conflicts. The execution, delivery and performance of
this Agreement does not conflict with, or constitute a breach or default under any of the charter or organizational documents of such Party, any law, order, judgment or governmental rule or regulation applicable to such Party, or any material
agreement, contract, commitment or instrument to which such Party is a party; and 
 10.1.5 Assignment of IP Rights.
Each employee, consultant, agent or Sublicensee of such Party performing work under this Agreement has, and during the Term will make a legally binding and outstanding present assignment of the rights of such employee, consultant, agent or
Sublicensee to any *** or Licensee Improvement to such Party. 
 10.2 Licensor’s Representations, Warranties and Covenants. Licensor
represents, warrants and covenants to Licensee that (i) it has the right to grant the rights and licenses granted herein ***; (ii) ***; (iii) ***; (iv) in the performance of this Agreement, or the exercise of any rights obtained
hereunder, Licensor will comply with all applicable laws, regulations, rules, orders and other requirements, now or hereafter in effect, and (v) ***. 
 10.3 Licensee’s Representations, Warranties and Covenants. Licensee represents, warrants and covenants to Licensor that in the performance of this Agreement, or the exercise of any rights
obtained hereunder, Licensee will comply with and will cause its Affiliates and Sublicensees to comply with, all applicable laws, regulations, rules, orders and other requirements, now or hereafter in effect. Licensee shall store, handle, transport,
use and dispose of Potelligent® CHOK1SV and Transfected Cells in accordance with all applicable country, state
and local laws and regulations. 

  
 *** INDICATES MATERIAL
THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.

  
 27 

			
	CONFIDENTIAL	  	Execution Copy

  

 10.4 DISCLAIMER OF WARRANTIES. EXCEPT AS SET FORTH IN THIS AGREEMENT, LICENSOR AND LICENSEE MAKE
NO REPRESENTATIONS AND EXTEND NO WARRANTIES OR CONDITIONS OF ANY KIND, EITHER EXPRESS OR IMPLIED (IN THE CASE OF LICENSOR, INCLUDING WITH RESPECT TO THE TECHNOLOGY), INCLUDING, BUT NOT LIMITED TO, WARRANTIES OF MERCHANTABILITY, FITNESS FOR A
PARTICULAR PURPOSE, VALIDITY OF THE PATENTS LICENSED HEREUNDER, OR NONINFRINGEMENT OF THE IP RIGHTS OF THIRD PARTIES. IN PARTICULAR, LICENSOR OFFERS NO REPRESENTATION OR WARRANTIES THAT THE USE OF ALL OR ANY PART OF THE TECHNOLOGY WILL RESULT IN THE
SUCCESSFUL COMMERCIALIZATION OF ANY PRODUCT FOR ANY PURPOSE. 
 10.5 MATERIALS DISCLAIMER. THE TRANSFECTION
SUPPLEMENTS, VECTORS AND POTELLIGENT® CHOK1SV TRANSFERRED PURSUANT TO THIS AGREEMENT, WHEN COMBINED WITH AN
ANTIBODY, ARE IN THE DEVELOPMENTAL STAGE AND MAY HAVE HAZARDOUS PROPERTIES. THE VECTORS, TRANSFECTION SUPPLEMENTS AND
POTELLIGENT® CHOK1SV ARE NOT FULLY TESTED AND, EXCEPT AS SET FORTH IN THIS AGREEMENT, PROVIDED “AS
IS”, WITH NO WARRANTIES, EXPRESS OR IMPLIED, INCLUDING WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. LICENSEE SHALL BEAR ALL RISK RELATING TO THE VECTORS, POTELLIGENT® CHOK1SV, AND TRANSFECTION SUPPLEMENTS TRANSFERRED TO LICENSEE, AND LICENSOR SHALL NOT BE LIABLE UNDER ANY CONTRACT, NEGLIGENCE, STRICT LIABILITY OR OTHER THEORY FOR
ANY DAMAGES INCLUDING DIRECT, INCIDENTAL OR CONSEQUENTIAL DAMAGES OR COST OF PROCUREMENT OF SUBSTITUTE GOODS, SERVICES OR TECHNOLOGY IN CONNECTION THEREWITH. 
 10.6 IP DISCLAIMER. EXCEPT AS OTHERWISE EXPLICITLY PROVIDED IN THIS AGREEMENT, NOTHING IN THIS AGREEMENT IS OR SHALL BE CONSTRUED AS: (i) A WARRANTY OR REPRESENTATION BY LICENSOR AS TO THE
VALIDITY, ENFORCEABILITY OR SCOPE OF ANY CLAIM WITHIN LICENSOR IP; (ii) A WARRANTY OR REPRESENTATION THAT ANYTHING MADE, USED, OFFERED FOR SALE, SOLD OR OTHERWISE DISPOSED OF UNDER ANY LICENSE GRANTED IN THIS AGREEMENT IS OR SHALL BE FREE FROM
INFRINGEMENT OF ANY PATENT RIGHTS OR OTHER IP RIGHTS OF A THIRD PARTY; (iii) AN OBLIGATION TO BRING OR PROSECUTE ACTIONS OR SUITS AGAINST THIRD PARTIES FOR INFRINGEMENT OF ANY OF THE LICENSOR IP RIGHTS; OR (iv) GRANTING BY IMPLICATION,
ESTOPPEL, OR OTHERWISE ANY LICENSES OR RIGHTS UNDER IP RIGHTS OF LICENSEE OR LICENSOR OR THIRD PARTIES, REGARDLESS OF WHETHER SUCH IP OR OTHER RIGHTS ARE DOMINANT OR SUBORDINATE TO ANY LICENSOR IP RIGHTS. 

  
 *** INDICATES MATERIAL
THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.

  
 28 

			
	CONFIDENTIAL	  	Execution Copy

  

 ARTICLE 11—INDEMNIFICATION 

11.1 Indemnification by Licensee. Licensee shall defend, indemnify and hold harmless Licensor, its Affiliates, and their respective directors,
officers, employees and agents from all claims, losses, damages and expenses, including reasonable legal expenses (“Losses”), each to the extent payable to a Third Party, resulting from suits, claims, actions, demands or other
proceedings, in each case brought by a Third Party (“Claims”) to the extent arising out of or relating to (i) the gross negligence, unlawful act or willful misconduct of Licensee (including its Affiliates and Sublicensees) in
connection with its or their performance of this Agreement; or (ii) the making, having made, distribution, sale, offer for sale or use of any Antibody or Product or the use of Licensor IP or the Licensed Technology by Licensee or its
Sublicensees, except to the extent that such Losses are the result of Licensor’s gross negligence, willful misconduct or unlawful act. 

11.2 ***. 
 11.3
Procedure. If either Party intends to claim indemnification under this Article 11, including on behalf of any of its Affiliates or its or their respective directors, officers, employees and agents, such Party (the “Indemnitee”)
shall promptly notify the other Party (the “Indemnitor”) in writing of any Claims of a Third Party for which the Indemnitee intends to claim such indemnification. Indemnitor shall have sole control of the defense and settlement of
any such Claim, provided that Indemnitee shall have the right to participate in, and, to the extent Indemnitor so desires, to assume the defense thereof with counsel mutually and reasonably satisfactory to the Parties. The obligations of this
Article 11 shall not apply to amounts paid in settlement of any Claims of Third Party if such settlement is effected without the consent of Indemnitor, which consent shall not be withheld, conditioned or delayed unreasonably. The failure to deliver
written notice to Indemnitor within a reasonable time after the commencement of any such action, if prejudicial to its ability to defend such action, shall relieve Indemnitor of any obligation to Indemnitee under this Article 11 to the extent such
Indemnitor was so prejudiced. Indemnitee, its or their employees and agents, shall reasonably cooperate with Indemnitor and its legal representatives in the investigation of any Claim covered by this Article 11. If the Parties cannot agree as to the
application of Section 11.1 or 11.2 as to any Claim, the Parties may conduct separate defenses of such Claim, with each Party retaining the right to claim indemnification from the other Party in accordance with Section 11.1 or 11.2 upon
resolution of the underlying Claim. 
 11.4 Insurance Proceeds. Any indemnification hereunder shall be made net of any insurance proceeds
recovered by the Indemnitee; provided, however, that if, following the payment to the Indemnitee of any amount under this Article 11, such Indemnitee recovers any insurance proceeds in respect of the Claim for which such
indemnification payment was made, the Indemnitee shall promptly pay an amount equal to the amount of such proceeds (but not exceeding the amount of such indemnification payment) to the Indemnitor. 

  
 *** INDICATES MATERIAL
THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.

  
 29 

			
	CONFIDENTIAL	  	Execution Copy

  

 11.5 Insurance. Each Party shall procure and maintain insurance policies underwritten by a
reputable insurance company or self-insurance, including clinical trial and product liability insurance, and providing adequate coverage for its respective obligations and activities hereunder. Notwithstanding the foregoing, Licensee and its
Affiliates shall procure or maintain policies of insurance for comprehensive general liability, clinical trials and products liability coverage in a minimum amount of US $*** with respect to Licensee’s performance under this Agreement.

 11.6 Limitation of Liability. LICENSOR SHALL NOT BE LIABLE TO LICENSEE AND LICENSEE SHALL NOT BE LIABLE TO LICENSOR FOR ANY
CONSEQUENTIAL, INCIDENTAL, PUNITIVE, SPECIAL OR INDIRECT DAMAGES, INCLUDING LOSS OF ANTICIPATED PROFITS, EXCEPT TO THE EXTENT ANY SUCH DAMAGES ARE REQUIRED TO BE PAID TO A THIRD PARTY AS PART OF A CLAIM FOR WHICH A PARTY PROVIDES INDEMNIFICATION
UNDER THIS ARTICLE 11. ***. 
 ARTICLE 12—DISPUTE RESOLUTION 

12.1 Dispute Resolution Philosophy and Process. Any dispute that may arise between Licensor and Licensee relating to the terms of this Agreement
or the activities of the Parties shall be referred to (i) an officer of Licensee and (ii) an officer of each of Lonza and BioWa (collectively, the “Management Representatives”), who shall attempt in good faith to achieve a
resolution of such dispute. If such Management Representatives are unable to resolve such a dispute within *** (***) Business Days of the first presentation of such dispute to such Management Representatives, such dispute shall be referred to an
appropriately senior officer of each of Lonza and BioWa and the an appropriately senior officer of Licensee (or their respective designees) who shall use their good faith efforts to mutually agree upon the proper course of action to resolve the
dispute. If any dispute is not resolved by these individuals (or their designees) within *** (***) Business Days after such dispute is referred to them, or such longer period as they may mutually agree, then Licensee or Licensor shall have the right
to pursue the dispute resolution mechanism provided in Section 12.2. 
 12.2 International Court of Arbitration. Any dispute that
may arise between Licensor and Licensee relating to the terms of this Agreement or the activities of the Parties that is not resolved pursuant to Section 12.1 shall be finally settled under the Rules of Arbitration of the International Chamber
of Commerce (“ICC”). The arbitration will be held in ***, before a single arbitrator knowledgeable in biotechnology-related matters and familiar with the biotechnology industry, selected in accordance with the rules and regulations
of the ICC. The arbitration will be conducted in the English language and in accordance with the rules and regulations promulgated by the ICC, unless specifically modified in this Agreement. The arbitration must commence within *** (***)

  
 *** INDICATES MATERIAL
THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.

  
 30 

			
	CONFIDENTIAL	  	Execution Copy

  

 
days of the date on which the arbitrator is selected. The arbitrator will have the power to order the production of documents by each Party and any Third Party witnesses; however, the arbitrator
will not have the power to order ***. Each Party must provide to the other, no later than *** (***) business days before the date of arbitration, the identity of all persons that may testify at the arbitration and a copy of all documents that may be
introduced at the arbitration or considered or used by a Party’s witness or expert. The arbitrator’s decision and award will be made and delivered as soon as reasonably possible and in any case within *** (***) months of the selection of
the arbitrator. The arbitrator’s decision must set forth a reasoned basis for any award of damages or finding of liability. The arbitrator will not have power to award damages in excess of actual compensatory damages unless expressly authorized
by this Agreement and may not multiply actual damages or award punitive damages or any other damages that are specifically excluded under this Agreement. The Parties covenant and agree that they will participate in the arbitration in good faith and
that they will share equally the costs of the arbitration, except as otherwise provided herein. Any Party refusing to comply with an order of the arbitrator will be liable for costs and expenses, including attorneys’ fees, incurred by the other
Parties in enforcing the award. Notwithstanding the foregoing to the contrary, in the case of temporary or preliminary injunctive relief, any Party may proceed in court without prior arbitration for the purpose of avoiding immediate and irreparable
harm. The provisions of this Section will be enforceable in any court of competent jurisdiction. 
 12.3 No Limitation. Notwithstanding
the foregoing, nothing in this Agreement shall be construed as limiting in any way the right of a Party to immediately seek temporary or preliminary injunctive relief from a court of competent jurisdiction with respect to any actual or threatened
breach of this Agreement. 
 ARTICLE 13—MISCELLANEOUS PROVISIONS 

13.1 Advice of Counsel. Licensee and Licensor have consulted counsel of their choice regarding this Agreement and each acknowledges and agrees
that this Agreement shall not be deemed to have been drafted by one Party or another and shall be construed accordingly. 
 13.2
Assignment. Licensee shall not assign this Agreement without the prior written consent of Licensor, except that Licensee may assign this Agreement without consent to an Affiliate, or to a successor to all or substantially all of its business or
assets to which this Agreement relates. No assignment shall relieve the assignor of its obligations which accrued prior to the date of assignment. If any permitted assignment by Licensee would result in withholding or other similar taxes becoming
due on payments to Licensor under this Agreement, Licensee shall be responsible for all such taxes and the amount of such taxes shall not be withheld or otherwise deducted from the amounts payable to Licensor. If, in such event, Licensor actually
reduces the amount of income tax paid by it as a result of using a credit for the amount of such withholding or similar taxes paid by Licensee, then Licensor shall promptly refund to Licensee the amount of such reduction in income tax resulting from
the use of such credit. If any permitted assignment by 

  
 *** INDICATES MATERIAL
THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.

  
 31 

			
	CONFIDENTIAL	  	Execution Copy

  

 
Licensor would result in withholding or other similar taxes becoming due on payments to Licensor, Licensee may withhold such taxes for the account of Licensor to the extent required by law and
treaty; Licensee will promptly provide Licensor with receipts from taxing authorities evidencing payment of all amounts withheld. 
 13.3
Binding Effect. This Agreement, the rights granted and obligations assumed hereunder shall be binding upon and shall inure to the benefit of Licensee, Licensor and their respective successors and permitted assigns. 

13.4 Counterparts. This Agreement may be executed in counterparts, or facsimile versions, each of which shall be deemed to be an original, and all
of which together shall be deemed to be one and the same agreement. 
 13.5 Entire Agreement. This Agreement and the exhibits and
schedules hereto and thereto, constitute and contain the entire understanding and agreement of the Parties respecting the subject matter hereof and thereof, and cancel and supersede any and all prior negotiations, correspondence, understandings and
agreements between the Parties, whether oral or written, regarding such subject matter. 
 13.6 Force Majeure. The failure of Licensor or
Licensee to timely perform any obligation under this Agreement by reason of epidemic, earthquake, riot, civil commotion, fire, act of God, war, terrorist act, strike, flood, or governmental act or restriction, or other cause that is beyond the
reasonable control of that Party shall not be deemed to be a material breach of this Agreement, but shall be excused to the extent and for the duration of such cause, and that Party shall provide the other Parties with full particulars thereof as
soon as it becomes aware of the same (including its best estimate of the likely extent and duration of the interference with its activities) and shall use commercially reasonable efforts to avoid or remove such cause, and shall perform its
obligation(s) with the utmost dispatch when the cause is removed. If the performance of any such obligation under this Agreement is delayed owing to such a force majeure for any continuous period of more than *** (***) days, the ***. 

13.7 Further Actions. Each Party agrees to execute, acknowledge and deliver such further instruments and to do all such other acts as may be
reasonably necessary or appropriate in order to carry out the purposes and intent of this Agreement. The Parties shall cooperate and use commercially reasonable efforts to make all other registrations, filings, and applications, to give all notices,
and to obtain as soon as practicable all governmental or other consents, transfers, approvals, orders, qualifications, authorizations, permits, and waivers, if any, and to do all other things necessary or desirable for the consummation of this
Agreement. 
 13.8 Governing Law. This Agreement shall be governed by and construed in accordance with the laws of the State of New York,
without regard to the application of principles of conflicts of law. 

  
 *** INDICATES MATERIAL
THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.

  
 32 

			
	CONFIDENTIAL	  	Execution Copy

  

 13.9 Interpretation. The captions and headings in this Agreement are for convenience only, and
are to be of no force or effect in construing or interpreting any provisions of this Agreement. Unless specified to the contrary, references to an Article, a Section or an Exhibit mean the particular Article, Section or Exhibit to this Agreement and
references to this Agreement include all Exhibits hereto. Unless the context otherwise clearly requires, whenever used in this Agreement: (i) the words “include” or “including” shall be construed to have the inclusive
meaning frequently identified with the phrase “including but not limited to” or “including without limitation;” (ii) the word “day” or “year” means a calendar day or year; (iii) the word
“notice” shall mean notice in writing (whether or not specifically stated) and shall include notices, consents, approvals and other written communications contemplated under this Agreement; (iv) the words “hereof,”
“herein,” “hereby” and derivative or similar words refer to this Agreement (including any Exhibits); (v) the word “or” shall be construed to have the inclusive meaning identified with the phrase
“and/or;”(vi) words of any gender include the other gender; (vii) references to the plural shall be deemed to include the singular and the plural, the part and the whole; and (viii) references to any specific law, rule or
regulation, or article, section or other division thereof, shall be deemed to include the then-current amendments thereto or any replacement law, rule or regulation thereof. 
 13.10 No Implied Licenses to Use of Name or Trademark. Except as otherwise specifically provided in Section 8.5, no right, express or implied, is granted by this Agreement to a Party to use in
any manner the name or any other trademark of any other Party. 
 13.11 Independent Contractors. Each Party is an independent contractor
under this Agreement. Nothing contained in this Agreement is intended nor is to be construed so as to constitute Licensee or Licensor as partners or joint venturers with respect to this Agreement. No Party shall have any express or implied right or
authority to assume or create any obligations on behalf of or in the name of any other Party, or to bind any other Party to any other contract, agreement or undertaking with any Third Party or Affiliate. 

13.12 Notices and Deliveries. Any formal notice, request, delivery, approval or consent required or permitted to be given under this Agreement
shall be in writing in English and shall be deemed to have been sufficiently given when it is received, whether delivered in person, transmitted by facsimile with contemporaneous confirmation by mail, delivered by certified mail (or its equivalent),
or delivered by courier service (receipt required), to the Party to which it is directed at its address shown below or such other address as such Party shall have last given by notice to the other Parties. 

 

			
	 If to Licensor:
	  	With a copy to:
		
	 BioWa, Inc.
	  	Alfred W. Zaher, Esq.
	 212 Carnegie Center, Suite 101
	  	Blank Rome LLP
	 Princeton NJ 08540, USA
	  	130 North 18th Street
	 Attn: Yasunori Yamaguchi, Ph.D., President and CEO
	  	Philadelphia, PA 19103
	 Fax: ***
	  	Fax: ***

  
 *** INDICATES MATERIAL
THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.

  
 33 

			
	CONFIDENTIAL	  	Execution Copy

  

			
	 And
	  	With a copy to:
		
	 Lonza Sales AG
	  	Lonza Biologics Plc
	 Munchensteinerstrasse 38
	  	228 Bath Road
	 Basel
	  	Slough, SL1 4DX
	 CH-4002, Switzerland
	  	United Kingdom
	 Attn: General Counsel
	  	Attn: Company Secretary
	 Fax: +41 61 316 91 11
	  	Fax: +44 1753 777 001

  

			
	 If to Licensee:
	  	With a copy to:
		
	 Five Prime Therapeutics, Inc.
	  	Five Prime Therapeutics, Inc.
	 Two Corporate Drive

South San Francisco, CA 94080
	  	 Two Corporate Drive
 South
San Francisco, CA 94080

	 Attn: Business Development

Fax: 415-365-5601
	  	 Attn: General Counsel
 Fax:
***

 13.13 Severability. If any provision of this Agreement becomes or is declared by a court of competent jurisdiction
to be illegal, unenforceable or void, this Agreement shall continue in full force and effect without said provision, so long as the Agreement otherwise continues to provide the Parties with materially the same benefits. If, without said voided
provision, the Parties are unable to realize materially the same benefits, the Parties shall negotiate in good faith to amend this Agreement to reestablish (to the extent legally permissible) the benefits as provided the Parties under this Agreement
on the Effective Date. 
 13.14 Amendments. No modification or amendment of any provision of this Agreement shall be valid or effective
unless made in writing and signed by a duly authorized officer of each Party. The failure of either Party to assert a right hereunder or to insist upon compliance with any term or condition of this Agreement shall not constitute a waiver of that
right or excuse a similar subsequent failure to perform any such term or condition. 
 13.15 Waiver. The waiver by any Party of any right
hereunder, or of any failure of any other Party to perform, or of any breach by the other Party, shall not be deemed a waiver of any other right hereunder or of any other breach by or failure of any other Party whether of a similar nature or
otherwise. 

  
 *** INDICATES MATERIAL
THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.

  
 34 

			
	CONFIDENTIAL	  	Execution Copy

  

 13.16 Exhibits. The exhibits attached to this Agreement shall form an integral part hereof. In
the event of any inconsistency between this Agreement and any exhibit, this Agreement shall prevail. 
 13.17 Section 365(n) of the
Bankruptcy Code. All rights and licenses granted under or pursuant to any section of this Agreement are, and shall otherwise be deemed to be, for purposes of Section 365(n) of the Bankruptcy Code, licenses of rights to “intellectual
property” as defined under Section 101(35A) of the Bankruptcy Code. The Parties shall retain and may fully exercise all of their respective rights and elections under section 365(n) of the Bankruptcy Code. 

(signature page follows) 

  
 *** INDICATES MATERIAL
THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.

  
 35 

			
	CONFIDENTIAL	  	Execution Copy

  

 IN WITNESS WHEREOF, the Parties have put their names and affixed their seals or
executed this Agreement and each Party shall have one (1) copy. 
  

									
	LONZA SALES AG	 		 	BIOWA, INC.
					
	By:	 	/s/ Gerry Kennedy	 		 	By:	 	/s/ Yasunori Yamaguchi
	Name:	 	Gerry Kennedy	 		 	Name:	 	Yasunori Yamaguchi
	Title:	 	Authorised Signatory	 		 	Title:	 	President and CEO
			
	LONZA SALES AG	 		 	
					
	By:	 	/s/ Una Hillery	 		 		 	
	Name:	 	Una Hillery	 		 		 	
	Title:	 	Authorised Signatory	 		 		 	
			
	FIVE PRIME THERAPEUTICS, INC.	 		 	
					
	By:	 	/s/ Lewis T. Williams, MD, PhD	 		 		 	
	Name:	 	Lewis T. Williams, MD, PhD	 		 		 	
	Title:	 	President and Chief Executive Officer	 		 		 	

  
 *** INDICATES MATERIAL
THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.

  
 36 

			
	CONFIDENTIAL	  	Execution Copy

  

 EXHIBIT 1 
 LICENSOR PATENTS 
  

													
	
Title                
	  	 Country
	  	Application No.	  	Publication No.	  	Filing Date
(y/m/d)	  	Patent No.	  	Issue Date

 *** 

  
 *** INDICATES TWO PAGES OF
MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.

  
 Exhibit 1-1

			
	CONFIDENTIAL	  	Execution Copy

  

 EXHIBIT 2 
 PROGRESS REPORT 
 *** 

  
 *** INDICATES THREE PAGES
OF MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED. 

  
 Exhibit 2-1

			
	CONFIDENTIAL	  	Execution Copy

  

 EXHIBIT 3 
 TRANSFECTION SUPPLEMENTS 
 *** 

  
 *** INDICATES ONE PAGE OF
MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.

  
 Exhibit 3-1

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00220-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00220-of-00352.parquet"}]]